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ABSTRACT 
 
 
Obesity has become a widespread concern to human health largely over 
the past three decades. It is thought that obesity is associated with the over 
consumption of calorically dense diets. The rewarding value of food is mediated 
through the mesolimbic dopamine system, though is less understood how 
appetitive control circuits relay information to existing reward circuitry.  The 
adiposity signaling hormone, leptin, is a critical mediator of food intake and fat 
storage. Leptin signaling, via the long form of the leptin receptor (LepRb), is 
predominantly carried out within the hypothalamus. Leptin action specific to the 
lateral hypothalamus area (LHA) modulates reward function via direct and 
indirect inhibition of reward circuitry.  Here, I have identified a novel leptin 
receptor population within the LHA that co-expresses the inhibitory neuropeptide 
galanin (termed Gal-LepRb neurons). To investigate the physiological function of 
leptin through Gal-LepRb neurons, we selectively deleted LepRb in galanin 
neurons (referred to as Gal-LepRbKO mice).  In a two-bottle-choice paradigm, I 
assessed nutrient selection for isocaloric lipid and sucrose solutions. 
Interestingly, Gal-LepRbKO mice demonstrated a significant preference for the 
sucrose solution and decreased lipid intake compared to controls.  Moreover, 
Gal-LepRbKO mice displayed stronger motivation to work for a sucrose treat.  My 
data further indicate that Gal-LepRb neurons are inhibitory acting neurons that 
are stimulated by leptin. Gal-LepRb neurons strongly innervate local orexin 
neurons and noradrenergic neurons in the locus coeruleus (LC).  Intriguingly, 
orexin neurons also strongly innervate the LC, and activation of orexin neurons 
	  	   xiv 
correlates with motivational and food-seeking behaviors. My data also show that 
orexin neurons express the Gi-coupled GPCR galanin 1-receptor (GalR1), 
validating the cellular ability of orexin neurons to respond to galanin.  In 
summary, we have characterized a novel population of LHA LepRb neurons and 
propose that leptin-mediated inhibition of orexin neurons, possibly via inhibitory 
galanin-GalR1 signaling, regulates the reward value of nutrients.
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CHAPTER 1. GENERAL INTRODUCTION 
 
 
1.1 LEPTIN 
 
  1.1.1 Leptin and energy balance.  Leptin is a 16kD peptide secreted from 
adipocytes and largely communicates information concerning energy stores to the 
brain (Zhang et al. 1994, Elmquist, Maratos-Flier, et al. 1998, Friedman 1998). 
Circulating leptin levels are correlated with the amount of fat mass present within an 
organism (Frederich et al. 1995, Maffei et al. 1995) and fasting-induced drops in 
leptin levels elicits a strong feeding response (Maffei et al. 1995). Leptin plays a 
critical role in energy balance regulation as mice lacking the capability to produce 
leptin, known as ob/ob mice, are morbidly obese, show marked increases in food 
intake (hyperphagia) and exhibit numerous metabolic-associated dysfunctions 
(Zhang et al. 1994, Montague et al. 1997, Clement et al. 1998). Although ob/ob 
mice exhibit an extreme obesity phenotype, the absence of leptin triggers a 
starvation signal thereby inducing a potent feeding response. Accordingly, 
administration of recombinant leptin to ob/ob mice and leptin deficient humans fully 
reverses obesity and corrects co-morbidity metabolic effects (Halaas et al. 1995, 
Ozata, Ozdemir, and Licinio 1999, Farooqi et al. 2002, Farooqi 2008). When first 
discovered, leptin was expected to be the long anticipated cure for obesity since 
treatment with recombinant leptin reduced body fat mass in both lean and ob/ob 
mice (Halaas et al. 1995).  However, this was not the case as diet-induced obese 
animals and obese humans exhibit markedly increased circulating leptin levels 
(Maffei et al. 1995, Considine et al. 1996, Frederich et al. 1995) and leptin 
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treatments only marginally decreased body weight in obese humans and rodents 
(Halaas et al. 1997, Heymsfield et al. 1999). These findings suggest a form of 
desensitization to leptin in the obese state. Therefore, it is important we unravel the 
diversity of leptin action in order to develop effective treatments to counteract or 
prevent obesity-induced leptin resistance. 
 1.1.2 Leptin receptor signaling and distribution. The leptin receptor gene 
encodes five alternatively spliced forms of the leptin receptor (Lep-Ra, Lep-Rb, Lep-
Rc, Lep-Rd, and Lep-Re) (Tartaglia et al. 1995, Lee et al. 1996). The LepR-b form 
is considered the long form of the leptin receptor due to its long cytoplasmic domain 
containing various motifs required for leptin-mediated signaling. Mutations in the 
long form of the leptin receptor, LepRb, result in an obese phenotype that strongly 
resembles the ob/ob mouse (Li et al. 1998). Thus, the anorexigenic (appetite 
decreasing) effects of leptin are predominantly carried out by LepRb. Leptin-
induced activation of the LepRb relies on the activity of janus kinase-2 (JAK2) which 
phosphorylates tyrosine residues associated with the receptor (Bjorbaek et al. 
2001). In vivo, leptin-induced activation of the LepRb stimulates JAK2-mediated 
phosphorylation of the signal transducer and activator of transcription-3 (STAT3) as 
shown in Figure 1.1 (Vaisse et al. 1996).  Phosphorylated-STAT3 (pSTAT3) then 
dimerizes and translocates into the nucleus prompting transcription of leptin 
responsive genes (Vaisse et al. 1996, Bjorbaek et al. 2001, Banks et al. 2000). 
Activation of STAT3 is crucial for leptin’s effects on body weight regulation, as 
mutations in tyrosine 1138 of the LepRb (the site of STAT3 phosphorylation; Figure 
1.1) leads to hyperphagia and obesity (Bates et al. 2003).  Leptin signaling via 
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LepRb also leads to tyrosine phosphorylation of the tyrosine phosphatase SHP-2 
which decreases the activity level of JAK2 to down-regulate LepRb activation 
(Carpenter et al. 1998). Additionally, the induction of downstream leptin effector 
SOCS-3 (suppressor of cytokine signaling-3) is also involved in negative feedback 
to the activated LepRb and is largely implicated in leptin resistance (Bjorbaek et al. 
1998). 
	  
Figure 1.1 Leptin-induced activation of pSTAT3 upon binding to the long form of the 
leptin receptor (LepRb).   
 
 In rodents and humans, leptin receptors are expressed in various nuclei 
throughout the central nervous system, but most prominent leptin action occurs 
within the hypothalamus.  The hypothalamus is the brain region largely recognized 
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for energy balance regulation.  Within the hypothalamus, LepRbs are expressed in 
the arcuate nucleus (ARC), ventromedial hypothalamus (VMH), dorsomedial 
hypothalamus (DMH), paraventricular hypothalamus (PVN) and the lateral 
hypothalamus area (LHA) (Mercer et al. 1996, Fei et al. 1997, Elmquist, Bjorbaek, 
et al. 1998).  As mentioned, the effects of leptin are generally associated with 
weight loss and reduced food intake (anorexia).  However, it is now widely 
acknowledged that the anatomical location of LepRb-expressing neurons dictates a 
very specific contribution to whole body energy balance (Berthoud 2007, Dhillon et 
al. 2006, van de Wall et al. 2008, Morton et al. 2003, Gao and Horvath 2007). For 
example, proopiomelanocortin (POMC)-expressing LepRb neurons in the ARC are 
critical for glucose homeostasis (Leinninger 2011, Balthasar et al. 2004, Berthoud 
2007, Elmquist et al. 2005, Morton et al. 2003, van de Wall et al. 2008), while 
glutamatergic (excitatory) LepRb neurons in the DMH are involved in body 
temperature regulation (Zhang et al. 2011).  Recently, LepRbs in the lateral 
hypothalamus area (LHA) that express the inhibitory neurotransmitter, gamma-
aminobutyric acid (GABA), have been highlighted for their role in reward function 
(Leinninger 2011, Leinninger et al. 2009). Taken together, the ability of leptin to 
regulate energy balance involves a complex integration of numerous and 
functionally distinct LepRb populations, many of which, have not been thoroughly 
characterized or possibly even identified. 
 
1.2 LEPTIN INFLUENCES REWARD CIRCUITS 
 
1.2.1 LHA-LepRb neurons and the mesolimbic dopaminergic system. 
The LHA has long been established for regulating reward-driven behaviors and 
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LHA neurons are highly responsive to food cues (Rolls, Burton, and Mora 1976, 
1980).  Early intracranial self-stimulation experiments revealed that rats will 
continuously perform a licking task in order to activate an electrode implanted into 
the LHA (Nakamura and Ono 1986). This suggests that general stimulation of LHA 
neurons induces a form of pleasure.  This effect also holds true for natural rewards 
as a large population of LHA neurons are stimulated when animals perform the 
same licking task for a glucose solution (Nakamura and Ono 1986). The LHA elicits 
these reward responses via activation of the mesolimbic dopaminergic system. 
Neurons in the LHA send dense projections to many limbic structures (ventral 
tegmental area, striatum, and pallidum) which act as critical regulators of motivated 
behavior. Namely, the mesolimbic dopaminergic system is comprised of dopamine 
(DA) neurons within the ventral tegmental area (VTA) that send long axonal 
projections to the nucleus accumbens (NAc; Figure 1.2).  Activation of the VTA-DA 
neurons and subsequent DA release within the NAc (VTAàNAc dopamine release 
termed mesoaccumbal DA) is believed to be the pathway responsible for 
encouraging reward-driven and motivated behaviors (Goto and Grace 2005, 
Berridge and Robinson 1998, Pecina et al. 2003, Ostlund et al. 2011). Previous 
experiments showed that leptin administration dampened motivated responses for 
LHA intracranial self-stimulation (Fulton, Woodside, and Shizgal 2000). Thus, 
circuits governing reward-motivated behaviors appear to converge with leptin 
signaling pathways. 
From a survival standpoint, it makes sense that pathways dictating nutrient 
intake would converge into the mesolimbic DA system to reinforce food seeking and 
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appetitive behaviors when energy stores are low. Due to their high-calorie content, 
sugar and fat-rich foods have evolved as potent stimulators of mesoaccumbal DA 
release (Hajnal, Smith, and Norgren 2004, Rada, Avena, and Hoebel 2005, Liang, 
Hajnal, and Norgren 2006). Thus, the evoked intensity of DA release is believed to 
encode the motivational properties (incentive value) for food rewards (Reilly 1999, 
Sclafani and Ackroff 2003, Wojnicki, Babbs, and Corwin 2010, Yoneda et al. 2007). 
Likewise, the anorexigenic effects of leptin are mediated, in part, through the 
inhibition of the mesolimbic DA system. Electrophysiological studies in brain slice 
preparations demonstrated that leptin inhibits firing of VTA DA neurons (Hommel et 
al. 2006). In behavioral studies, leptin was shown to attenuate sucrose seeking and 
sucrose consumption in rats (Figlewicz et al. 2001, Figlewicz et al. 2006). Together, 
these observations suggest that leptin’s inhibitory influence over DA neurons acts to 
decrease the incentive value of a food reward. On the contrary, electrically 
stimulated DA release in the NAc is markedly reduced in leptin deficient ob/ob mice 
(Fulton et al. 2006). Therefore, the function of leptin is contradictory in the literature; 
suggesting either inhibitory or stimulatory leptin action on VTA DA neurons.  
Clarifying the role of leptin in the regulation of the mesolimbic dopaminergic system 
is critical to understand the mechanism by which leptin modulates nutrient reward.  
Recent data indicates that LHA LepRb neurons project to VTA neurons and 
modulate food intake (Leinninger et al. 2009). The established LHA-LepRb circuit, 
shown in Figure 1.2, illustrates that leptin signaling in the LHA would directly 
modulate mesoaccumbal DA function.   Whether leptin would induce its effects 
through inhibition or stimulation of mesoaccumbal DA release is matter that 
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remains controversial. Therefore, determining the specific contribution of LHA-
LepRb neurons in the regulation the mesolimbic dopamine system would provide 
a functional pathway for understanding how the nutritional state of the body 
regulates reward-based feeding. 
 
Figure 1.2 Schematic illustrating the established circuitry of LHA-LepRb neurons 
into the mesolimbic dopaminergic system. LHA-LepRb regulates the mesolimbic 
dopamine system both directly via projections to the VTA and indirectly via 
innervation of local orexin neurons. 
 
 
1.2.2 Leptin regulates orexin’s neuronal activity. In addition to sending 
direct projections to the VTA, LHA LepRb-expressing neurons also innervate local 
orexin neurons as shown in Figure 1.2 {(Louis et al. 2010) and our own data 
detailed in Chapter 4}.  Orexin neurons are exclusively found within the LHA where 
they are co-mingled but not co-expressed with LHA LepRb neurons {(Louis et al. 
2010, Leinninger et al. 2009) and our data shown in Chapter 2}. Importantly, orexin 
neurons regulate various aspects of reward function largely via direct activation of 
the VTA-DAàNAc pathway {illustrated in Figure 1.2 (Peyron et al. 1998, Fadel and 
LV 
4V 
LHA 
 LepRb 
VTA 
NAc 
DA Release 
ORX 
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Deutch 2002, Baldo et al. 2003)}. Typically, orexin neurons are activated in 
response to low serum glucose levels (Cai et al. 1999, Moriguchi et al. 1999) as 
also seen during fasting (Sakurai et al. 1999), and activation of orexin neurons is 
strongly correlated with food/reward-seeking behaviors (Harris, Wimmer, and 
Aston-Jones 2005). Central administration of the orexin peptide increases the 
incentive motivation to work for sucrose pellets, while central (VTA) injections of 
orexin receptor antagonists block this effect (Choi et al. 2010). Activation of orexin 
neurons is also triggered by environmental cues that predict the arrival of a 
palatable food reward; a mechanism thought to enhance food anticipatory and 
seeking behaviors (Harris, Wimmer, and Aston-Jones 2005). Thus, the activity of 
orexin neurons, and subsequent mesoaccumbal DA response, relies on both 
nutritional signals regulating energy balance as well as environmental cues 
predictive of food rewards. 
As mentioned, leptin is primarily considered a signal of nutritional status, but 
it also modulates reward function via inhibition of the mesolimbic DA system.  This 
effect occurs, partly, via leptin-mediated inhibition of orexin neurons.  In 
electrophysiological recordings from brain slice preparations, leptin application 
reduced the firing frequency of orexin neurons (Yamanaka et al. 2003), and this 
was observed by a reduction of excitatory inputs onto orexin neurons (Yamanaka et 
al. 2003, Cai et al. 1999, Horvath and Gao 2005).  Leptin treatment also attenuates 
food/reward-driven behaviors that are associated with the activation of orexin 
neurons, as sucrose-seeking behaviors are significantly decreased following a 
leptin injection (Figlewicz et al. 2006). Since LHA LepRb neurons innervate local 
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orexin neurons, it seems highly likely that leptin action specific to LHA LepRb 
neurons would regulate food/reward-motivated behaviors via inhibition of orexin 
neurons. However, the precise LepRb population mediating this effect has yet to be 
identified. 
 
1.3 CHARACTERIZATION OF CENTRAL GALANIN ACTION 
As previously eluded to, the discrete distribution patterns of LepRb-
expressing neurons throughout the brain suggest that each LepRb population 
contributes to distinct aspect of leptin action. This idea is reinforced by the fact that 
LepRb neurons exhibit differential molecular and neurochemical properties based 
on their anatomical position within the brain. Specific to the LHA/perifornical area 
(PFA) we have identified a novel subpopulation of LepRb neurons that co-express 
the neuropeptide galanin, which we refer to as Gal-LepRb neurons.  Leptin 
mediates anorexigenic action via LepRb; however, central galanin signaling is often 
recognized for evoking orexigenic (appetitive) effects.  Thus, we aim to understand 
how leptin regulates central galanin signaling via Gal-LepRb neurons and 
determine how galanin’s effects in this novel LepRb population would translate into 
aspects of feeding and body weight regulation.  
1.3.1 Galanin introduction. Galanin is a 29 amino acid peptide that is 
widely expressed throughout the brain and periphery and functions in various 
physiological processes. Centrally, galanin elicits its inhibitory effects both directly 
as galanin decreases the spontaneous firing of neurons in the locus coeruleus (LC) 
(Seutin et al. 1989) and indirectly as presynaptic galanin action inhibits glutamate 
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release in the ARC (Kinney, Emmerson, and Miller 1998). Galanin’s inhibitory 
effects are mediated through the activation of any of its three known G-protein 
coupled receptors: GalR1, GalR2 and GalR3 (Figure 1.3).  Specifically, GalR1 is 
widely expressed in the brain and galanin signaling via GalR1 has been recognized 
to modulate reward via palatable food selection and opioid-mediated reward 
function (Zorrilla et al. 2007, Holmes et al. 2012). GalR1 signals via Gi-pathway to 
reduce adenyl cyclase activity and thus induce the subsequent reduction in the 
cAMPà protein kinase A (PKA)à cAMP response element binding protein (CREB) 
pathway. Since galanin-GalR1signaling decreases CREB phosphorylation, pCREB 
can be used as a marker to assess galanin’s involvement in reward circuits (Hawes, 
Narasimhaiah, and Picciotto 2006). 
1.3.2 The role of galanin in macronutrient selection. Galanin signaling 
within the hypothalamus has prominent effects on food intake and fat deposition.  In 
contrast to the anorexigenic-acting hormone leptin, centrally administered galanin 
stimulates feeding (Tachibana et al. 2008). Furthermore, when rodents are allowed 
to choose between distinct macronutrients, galanin evokes the preferential intake of 
fats over carbohydrates and proteins (Tempel, Leibowitz, and Leibowitz 1988).  
Consistently, galanin deficient mice or central injections of galanin receptor 
antagonists are shown to reduce fat consumption (Adams et al. 2008, Odorizzi et 
al. 2002). A positive feed-forward mechanism is thought to further drive fat intake, 
as the consumption of a high fat diet increases hypothalamic galanin gene 
expression (Leibowitz et al. 2004). 
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Adapted from Hökfelt T, Experienta Supplementum, 2010 
 
Figure 1.3 Signal transduction of galanin’s 3 known G-protein coupled receptors: 
GalR1, GalR2, and GalR3 
 
As mentioned, palatable food intake is partly regulated via galanin activation 
of GalR1.  GalR1-deficient mice decrease their caloric intake when put on a high fat 
diet, despite their initial increased consumption in the 3-day acclimation to high fat 
(Zorrilla et al. 2007). Interestingly, GalR1 deficient mice show normal feeding 
behaviors on a standard chow diet, suggesting a specific role for galanin signaling 
via GalR1 in regulating fat intake. 
1.3.3 The role of galanin in opioid-mediated reward. Galanin is also 
widely recognized for its role in reward and addiction pathways, specifically via 
modulation of opioid neurotransmission.  Like galanin, opioids are potent 
stimulators of food intake and localized NAc injections of µ-opioid receptor agonists 
preferentially increases lipid consumption (Zhang, Gosnell, and Kelley 1998). 
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Central administration of galanin receptor agonists decreases opiate reward and 
attenuates opioid withdrawal symptoms (Zachariou, Parikh, and Picciotto 1999, 
Holmes et al. 2012). Consistently, galanin deficient mice experience both increased 
reward and withdrawal from opioids (Hawes et al. 2008), which appears to be 
largely regulated via GalR1 (Holmes et al. 2012). Galanin binding also seems to be 
high within dopaminergic areas of the brain (Hawes and Picciotto 2004), implicating 
a possible role for galanin in motivated feeding behaviors.  
Previous reports investigating the interaction between leptin and galanin 
have been largely inconsistent; claiming leptin may decrease (Sahu 1998b, a) or 
increase (Cheung et al. 2001) galanin gene expression, or has no effect on galanin 
gene expression at all (Williams et al. 1991). Such discrepancies are due to poor 
visualization of galanin- and LepRb-expressing neurons via antibody detection 
methods. Therefore, determining their accurate co-expression patterns would be 
extremely difficult. Thus far, the role galanin plays in nutrient reward has not been 
investigated using novel state of the art technologies such as transgenic or 
Cre/LoxP genetic mouse models.  To appropriately investigate a potential 
interaction between central galanin and leptin signaling, we implement neuron-
specific Cre/LoxP technologies to generate genetic mouse lines for: 1). accurate 
visualization of galanin and LepRb neurons via green fluorescent protein (GFP) 
reporter lines, 2). galanin and LepRb neuronal circuit tracing studies 3). developing 
a galanin-specific LepRb Knock Out (KO) mouse line. Here we aimed to establish 
the importance of leptin action specific to galanin neurons for modulating energy 
balance and potentially properties of nutrient reward. 
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CHAPTER 2. LEPTIN RECEPTOR NEURONS IN THE MOUSE 
HYPOTHALAMUS ARE COLOCALIZED WITH THE NEUROPEPTIDE 
GALANIN AND MEDIATE ANOREXIGENIC LEPTIN ACTION1 
 
2.1 INTRODUCTION 
Leptin controls energy homeostasis centrally via neurons that express the 
long form leptin receptor (LepRb). Several LepRb populations have been identified 
based on their anatomical location, co-expression of neuropeptides or other marker 
genes (Balthasar et al. 2004, Coppari et al. 2005, Dhillon et al. 2006, Hayes et al. 
2010, Leinninger et al. 2009, van de Wall et al. 2008), which helped to clarify their 
commensurate contribution to full leptin function. In fact, most LepRb populations 
studied showed a significant, but surprisingly mild, contribution to full leptin function. 
However, the majority of LepRb subpopulations have not been studied in detail, 
largely due to the lack of specific markers for significant subpopulations of LepRb 
neurons.  
Galanin is an orexigenic neuropeptide and galanin neurons are found 
throughout the brain, but a particularly dense population exists in the dorsomedial 
hypothalamus. However, orexigenic galanin action is mediated by the 
paraventricular nucleus (PVN), because PVN galanin injections most prominently 
increase food intake (Kyrkouli et al. 1990). The literature involving a possible 
interaction of galanin and leptin is very inconsistent. Some studies suggest contrary 
galanin and leptin action, because genetic deletion of galanin amplifies leptin-
induced weight loss (Hohmann et al. 2003, Hohmann et al. 2004). This may involve 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  Reprinted with permission of the American Journal of Physiology-Endocrinology 
and Metabolism 
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leptin-mediated regulation of galanin gene expression, even though the 
experimental data is scarce and experiments are difficult to compare due to 
different experimental approaches, detection methods and anatomical areas 
investigated. This may explain the inconsistent results showing that leptin may 
decrease (Sahu 1998b, a) or increase (Cheung et al. 2001) galanin gene 
expression, or does not effect galanin gene expression at all (Williams et al. 1991). 
Likewise, it is unclear if leptin directly or indirectly acts on galanin neurons, 
again demonstrated in controversial results showing that LepRb is either rarely 
(Cheung et al. 2001) or extensively (Hakansson et al. 1999, Iqbal et al. 2001) co-
localized with galanin in the hypothalamus. Both LepRb- and galanin-expressing 
neurons cannot be easily visualized immunohistochemically.  Galanin is rapidly 
transported into neuronal processes, so that immunohistochemical (IHC) staining 
for galanin cannot visualize cell bodies, unless animals are treated with colchicine 
to prevent vesicular galanin transport into processes (Perez et al. 2001). LepRb is 
expressed in low quantity, so that available LepRb specific antibodies are not 
sensitive enough to detect LepRb cell bodies, but LepRb-responsive neurons can 
be easily and reliably detected by leptin-induced phosphorylation of STAT3 (Faouzi 
et al. 2007, Munzberg, Flier, and Bjorbaek 2004, Zhang et al. 2011). However, such 
signaling pathways are blocked by colchicine treatment, so that LepRb and galanin 
cannot be easily detected together. Thus, in this study we aimed to reinvestigate 
the co-expression of galanin and LepRb and to start to evaluate if and how galanin 
may mediate physiological leptin action. To do this we used mice with transgenic 
green fluorescent protein (GFP) expression from the galanin promoter to 
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systematically characterize the existence, anatomical location and chemical nature 
of such Gal-LepRb neurons.  
 
2.2 MATERIALS AND METHODS 
2.2.1 Mouse strains. To visualize galanin expressing neurons we used male 
BAC transgenic mice (FVB background) with green fluorescent protein (GFP) 
expression under the control of the galanin promoter {GalTgGFP, Stock Tg(Gal-
EGFP109Gsat, identification number 0163420UCD}, which were obtained from the 
Mutant Mouse Regional Resource Center (MMRRC, http://www.mmrrc.org ), a 
NCRR-NIH funded strain repository, and were donated to the MMRRC by the 
NINDS funded GENSAT BAC transgenic project (http://www.gensat.org ). GalTgGFP 
mice and LepRbGFP mice used in this experiment were bred in-house by crossing 
FVB wildtype mice with hemizygous GalTgGFP or by crossing double homozygous 
LepRbGFP mice, respectively. Male LepRbGFP mice on a mixed background were 
used to visualize LepRb neurons and were derived from the colony of Dr. Martin 
Myers (University of Michigan, Ann Arbor, MI) and has been described in detail 
elsewhere (Leshan et al. 2006). Male C57/B6 mice were obtained from Jackson 
Laboratory (Bar Harbor, MA). All animals were group housed at a 12:12h light: dark 
cycle with ad libitum access to food and water unless stated otherwise. All animal 
breeding and experimental procedures were approved by the Institutional Animal 
Care and Use Committee and Pennington Biomedical Research Center.  
2.2.2 Peripheral leptin treatment. To identify LepRb neurons via leptin-
induced pSTAT3 induction, we treated GalTgGFP mice (n=3) or LepRbGFP mice (n=2) 
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intraperitoneal (i.p.) with leptin (5 mg/kg body weight) and perfused them 1h later. 
The leptin dose and incubation time were used based on earlier studies showing 
that leptin-induced pSTAT3 greatly co-localized with LepRb-GFP expressing 
neurons (Faouzi et al. 2007, Leinninger et al. 2009, Leshan et al. 2009, Zhang et al. 
2011). Leptin was obtained from Dr. Parlow (National Hormone and Peptide 
Program, http://www.humc.edu/hormones). For studies investigating leptin-induced 
cFos (as a surrogate of neuronal activity) in LepRb neurons, we treated LepRbGFP 
mice with PBS or leptin (5 mg/kg, i.p.) and perfused for brain fixation after 3 hours 
(n=3-4 per group). Following treatments animals were perfused as described below 
in section 2.2.7. 
2.2.3 In situ hybridization. To verify correct transgenic galanin-GFP 
expression we compared the distribution of GFP expression with the known 
distribution of galanin mRNA expression. Galanin in situ hybridization (ISH) data 
were used from the Mouse Allen Brain Atlas (Seattle, WA) and were available via 
http://www.brain-map.org. Reproduction of ISH images was with permission of the 
Allen Institute for Brain Science. 
2.2.4 Chronic cannulations for central injections. For central injections 
we chronically implanted single cannulas (Plastics One C353, Roanoke, VA) into 
the lateral ventricle (-0.3mm caudal, 1mm lateral and 2.1mm ventral to Bregma) or 
into the exPFA (-1.8mm caudal, -0.9mm lateral and -4.25mm ventral to Bregma in 
GalTgGFP mice and -1.1mm caudal, 0.9mm lateral and 4.75mm ventral to Bregma in 
C57B6 mice). GalTgGFP (n=2, for colchicine injection into the lateral ventricle, n=8 for 
intra exPFA cannulation) or C57/B6 mice (n=12) were deeply anesthetized with 1-
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3% isofluorane/oxygen and the head was mounted on a stereotaxic frame (M1900 
Stereotaxic alignment system, Kopf instruments, Tujunga, CA). An incision was 
made to expose the skull and an access hole was drilled to insert the guide 
cannula, which was secured in place with Loctite 454 (Fisher, Pittsburgh, PA) and 
dental cement before the wound was closed with wound clips. A dummy cannula 
was inserted into the guide and analgesia treatment was performed systemically 
every 12 hours for 2 days with buprenorphine (10 mg/kg) and once locally to the 
incision site with bupivacaine/lidocaine (2.5-12.5 mg/kg).  Animals were recovered 
for 1 week after surgery before injections were performed.  
2.2.5 Colchicine treatment. To allow efficient visualization of neurotensin 
(Nts) in GalTgGFP mice (n=2), we injected a single dose of freshly diluted colchicine 
(1 µl of 10 µg/µl colchicine in sterile saline; Sigma, St. Louis, MO) into the lateral 
ventricle.  24 hours post-colchicine injections mice underwent transcardiac 
perfusion with 10% neutral buffered formalin for tissue fixation and brains were 
extracted for further processing. 
2.2.6 Central leptin treatment and measurement of metabolic 
parameters. GalTgGFP mice and wildtype C57/B6 mice with unilateral exPFA 
cannulation were habituated to the metabolic chamber for 3 days. After that, mice 
were monitored daily for body weight and food intake and continuously for oxygen 
consumption, carbon dioxide production and locomotor activity (CLAMS, Columbus 
Instruments; Columbus, OH).  After 3 days of baseline data collection, mice were 
divided into two groups, one group (n=3-6) received a single leptin injection {dose: 
20 ng/100 nl sterile phosphate buffered saline (PBS)} and the other group (n=3-6) 
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received 100 nl PBS, injections were performed at a rate of 10 nl/60 s to give time 
for volume absorption. Leptin doses were used that we found earlier to be sufficient 
(20 ng) or insufficient (1 ng) to produce a measureable leptin response after central 
intracerebroventricular (i.c.v.) injections (Faouzi et al. 2007). Data collection was 
continued for 4 days post-injection. Mice were allowed to recover for 1 week in 
home cages after the last day of measurements. The experiment was then 
repeated with a lower leptin dose (1 ng/100 nl) and groups were crossed over so 
that each mouse received leptin only once during the studies (1 or 20 ng). At the 
end of the study, animals were perfused and analyzed for correct cannula 
placement, and two mice were removed from the studies due to cannula 
misplacement (see arrow in Figure 2.11D).   
2.2.7 Perfusion and immunohistochemistry. For perfusions animals were 
deeply anesthetized with an overdose of pentobarbital (60 mg/kg) and transcardiac 
perfusion with ice cold physiological saline for 30 seconds and ice cold 10% neutral 
buffered formalin (Sigma, St. Louis, MO) for 5 minutes. Brains were removed, post 
fixed overnight in fixative, transferred to 30% sucrose for 48 hours before 
cryosectioning into 4 representative series per brain of 30 µm sections on a sliding 
microtome. For immunohistochemistry (IHC) procedures, free-floating tissue 
sections were used. Nuclear peptides (cFos or pSTAT3) were stained first and 
developed with the diaminobenzidine (DAB) method. Staining with additional 
primary antibodies were performed (neuropeptides and GFP) and detected with 
fluorescent-labeled secondary antibodies, Alexa568 (neuropeptides) or Alexa488 
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(GFP; refer to List of Primary Antibodies on page xi for primary antibody 
description).  
For nuclear DAB IHC detection of pSTAT3 and cFos, the tissue was 
pretreated with 0.3% hydrogen peroxide in methanol for 20 minutes to block 
endogenous peroxide, followed by a 10 minute treatment in 0.3% glycine in 
phosphate buffered saline (PBS), and an additional 10 minute treatment in 0.03% 
sodium dodecyl sulfate in PBS. After that, sections were blocked for 3 hours in 3% 
normal donkey serum in PBS/0.25% Triton X-100/0.2% sodium azide. pSTAT3 or 
cFos antibodies were added (rabbit anti-pSTAT3, 1:1000 or rabbit anti-cFos, 1:3000 
in blocking solution) and incubated overnight at 4C. On the next day, sections were 
washed with PBS, incubated with a biotinylated secondary donkey anti-rabbit 
antibody for 1 hour (1:1000, in blocking solution without sodium azide). A 
biotinylated-horseradish peroxidase (HRP) enzyme is pre-incubated (1 hour) with 
free avidin to form the avidin-biotin complex (ABC solution: per 10 mL PBS= 20 µL 
avidin solution + 20 µL of biotin solution) and sections are then incubated in the 
ABC solution (Vector Laboratories, Burlingame, CA) for 1 hour. Finally, the signal 
was developed by 1x DAB solution (Pierce DAB Substrate Kit, ThermoScientific; 
Waltham, MA) giving a brown precipitate.  Sections were then washed with PBS 
and staining with additional primary antibodies was performed (neuropeptides and 
GFP) and detected with fluorescent-labeled secondary antibodies, Alexa 568 
(neuropeptides), or Alexa 488 (GFP). Sections were mounted onto gelatin-subbed 
slides and cover slipped with Pro-Long Anti-fade mounting medium (Invitrogen; 
Carlsbad, CA) for further microscopy analysis. 
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2.2.8 Antibody characterization.  The anti-pSTAT3 antibody stains a single 
band of 80kDa molecular weight on Western blots after stimulation with ciliary-
neurotrophic-factor (CNTF; manufacturer’s technical information). The specific 
detection of leptin-induced pSTAT3 was originally characterized by comparison of 
pSTAT3 signal in vehicle versus leptin-stimulated brain sections by Western blots 
and IHC (Faouzi et al. 2007, Munzberg, Flier, and Bjorbaek 2004, Munzberg et al. 
2003); in both cases leptin robustly increased pSTAT3 signals. Furthermore, 
induction of pSTAT3 by leptin was found in an anatomical distribution similar to in 
situ hybridization signals for LepRb (Munzberg, Flier, and Bjorbaek 2004, Munzberg 
et al. 2003, Faouzi et al. 2007) and conditional deletion of LepRb in steroidogenic 
factor 1 (SF1) or proopiomelanocortin (POMC) neurons resulted in SF1 and POMC 
specific lack of leptin-induced pSTAT3, respectively (Dhillon et al. 2006, Plum et al. 
2006). Specificity of anti-CART and anti-galanin has been tested by omitting the 
primary antibody and pre-adsorbing the antibody with the immunogen, which 
resulted in all cases in a complete lack of staining for all sections (Dun et al. 2000, 
Sherin et al. 1998). Specificity of anti-MCH (melanin concentrating hormone), -
orexin, -neurotensin and –TH (tyrosine hydroxylase) was verified by analysis of 
their typical distribution pattern as reported by others (Aston-Jones, Zhu, and Card 
2004, Swanson, Sanchez-Watts, and Watts 2005). Anti-GFP antibodies were 
verified by immunohistochemical staining of brains from LepRbGFP reporter mice 
compared with control mice that do not express GFP (unpublished data) and by co-
localization of LepRbGFP with leptin-induced pSTAT3 {Figure 2.3 and (Zhang et al. 
2011)}.   
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The anti-cFos antibody recognizes the 55kDa cFos and 62kDa v-Fos 
proteins and does not cross-react with the 39kDa Jun protein (manufacturer’s 
technical information). Specificity of anti-cFos has been tested by omitting the 
primary antibody and pre-adsorbing the antibody with the immunogen, which 
resulted in all cases in a complete lack of staining in all sections (Elmquist et al. 
1997).  
2.2.9 Leptin induced gene expression. For assessment of leptin regulated 
gene expression in the exPFA of ob/ob mice (8-10 weeks old) were treated twice 
daily with leptin (i.p. 5 mg/kg body weight) or PBS over 3 days (n=6 per group). On 
the 3rd day the last injection was given in the morning and tissue was collected 2 
hours later. Animals were anesthetized with pentobarbital (60 mg/kg) and 
decapitated for rapid brain removal. Brains were sliced in a pre-cooled rodent brain 
matrix for mice (Electron Microscopy Sciences, Hatfield, PA) consisting of 1mm, 
coronal dividers, and the exPFA and ARC were harvested from a 1mm coronal 
brain slice (approximately -1 to -2 mm caudal from Bregma). To obtain consistent 
tissue pieces we used the mammillothalamic tracts (mt) as landmarks to cut 
horizontal to the 3rd ventricle (defining the dorsal border of the exPFA). Another cut 
was made through the mt parallel to the 3rd ventricle (defining the lateral border of 
the exPFA) and a 3rd cut was made laterally to remove any remaining 
cortex/amygdala structures. No ventral cut was performed, maintaining the natural 
ventral base of the exPFA. The ARC piece was collected from the ventral portion of 
the remaining midline piece. RNA was isolated with the ToTALLY RNA kit (Ambion, 
Carlsbad, CA) and 350 ng RNA was used as template for the generation of cDNA 
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(RETROscript kit, Ambion, Carlsbad, CA). For quantitative PCR 10.5 ng template 
cDNA was used to determine gene expression using Taqman assays for SOCS3 
(Mm00545913_s1), galanin (Mm01236508_m1) and GAPDH (Mm99999915_g1), 
the latter served as housekeeping gene. Fold induction of gene expression with 
leptin was analyzed with the ΔΔCt method (also known as the comparative Ct 
method) as determined by the following equation: ΔΔCt = ΔCt, treatment - ΔCt, 
control. Here, the ΔCt treatment is the Ct value for the sample normalized to the 
endogenous housekeeping gene (GAPDH) and ΔCt-reference is the Ct value for the 
control also normalized to the endogenous housekeeping gene.  
2.2.10 Estimates of cell counts. We counted the number of LepRb neurons 
that were co-localized with cFos (as a surrogate for stimulated neurons) after PBS 
or leptin treatment to evaluate whether leptin would stimulate or inhibit exPFA 
LepRb neurons. Immunohistochemical staining for cFos and GFP (LepRbGFP) was 
visualized with a fluorescent microscope (Olympus BX51) and images were taken 
with a digital camera (Olympus DP30BW) using appropriate filters for fluorophores 
or bright-field illumination for DAB stain.  Images for cFos and GFP were taken at 
identical sites, superimposed, and pseudocolored using Olympus Software and 
Adobe Photoshop (Adobe Systems, San Jose, CA). Brightness and contrast were 
modified for all images to enhance visibility of nuclear pSTAT3 and cFos staining 
for figure preparation and cell counts, however, care was taken that all images 
within an experiment were modified with identical settings. For each brain (n=3-4 
per group) images from 4 anatomical levels were taken, representing the rostro-
caudal extension of the exPFA (from Bregma –1.8 to –2.1 mm, as seen in Figure 
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2.5).  Because the exPFA consists of 3 anatomically different locations (including 
the DMH, perifornical area and lateral hypothalamus) that may respond differently 
to stimuli, we subdivided the exPFA into 3 sub-areas for analysis: lateral 
hypothalamus (LH), perifornical area (PFA) and the DMH. A vertical line through the 
fornix separated the LH and PFA. The DMH and PFA were separated by a vertical 
line based on the distribution of DMH LepRb neurons. The total number of 
LepRbGFP neurons and cFos/GFP neurons were estimated by cell counts from 
digital images. The total number of GFP neurons within anatomical sites was 
analyzed to ensure comparison of similar GFP populations among animals.  The 
number of cFos/GFP neurons was expressed as percentage of the total number of 
GFP neurons in the quantified area.  The described cell counts are not intended to 
provide precise numbers of stimulated GFP neurons.  They instead served as 
estimates for a mainly stimulatory or inhibitory action of leptin in LepRb neurons.  
To evaluate the number and percentage of galanin-GFP/pSTAT3 neurons 
in the exPFA compared to the total number of galanin or pSTAT3 neurons, as well 
as to identify co-expression of CART with galanin-GFP/pSTAT3 neurons we 
counted cells from GalTgGFP mice (n=3) that were treated with 1 hour leptin (leptin 
administered 1 hour before perfusion) and every 4th section was stained for 
pSTAT3, GFP and CART. For each brain 4 sections containing the exPFA were 
used to determine the number of total pSTAT3, total galanin-GFP, galanin-
GFP/pSTAT3 double labeled neurons and galanin-GFP/pSTAT3/CART triple 
labeled neurons within the exPFA. The total number as well as percentage of 
galanin-GFP/pSTAT3 neurons based on total pSTAT3 or total galanin-GFP 
	  	   24 
neurons was expressed. For CART co-localizations the mean number of 
pSTAT3/GFP/CART neurons was expressed as a percentage of total 
pSTAT3/GFP neurons in the exPFA. 
We further evaluated the extent of co-localization for galanin and neurotensin 
neurons in colchicine treated GalTgGFP mice (n=2). While extensive co-localization 
was easily visible, we performed cell count estimates from four exPFA sections of a 
single brain. The number of total Nts neurons and Nts/GFP neurons in the exPFA 
were determined and Nts/GFP neurons were expressed as the percentage of total 
exPFA Nts neurons. 
For orexin and MCH co-localization we evaluated the co-localization of 
pSTAT3/galanin-GFP with orexin and MCH from GalTgGFP mouse brains (n=3). 
Because we did not observe any co-localization of pSTAT3 or galanin-GFP with 
orexin or MCH we did not perform cell counts and instead report the anatomical 
evidence for lack of co-localization with images.  
2.2.11 Statistical analysis.  Data were analyzed by student’s t-test (two 
group comparison) or by one-way repeated measure ANOVA followed by a Holm-
Sidak test for pairwise comparisons. The statistical tests used are specified 
accordingly in the figure legends and a significance level of p<0.05 was used in all 
tests.  
 
2.3 RESULTS 
 
2.3.1 Verification of GalTgGFP mice. To verify correct anatomical expression 
of galanin-GFP in GalTgGFP mice we compared GFP expression to in situ 
hybridization of galanin mRNA expression in adult mice (in situ data kindly provided 
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by the Allen Brain Institute, Figure 2.1, A-D). Indeed, galanin-mRNA expression 
patterns throughout the brain are very similar; this is illustrated in detail for the 
hypothalamus (Figure 2.1, A and B) and locus coeruleus (Figure 2.1, C and D).  
It is well known that adrenergic neurons in the locus coeruleus are highly co-
expressed with galanin (Holets et al. 1988, Melander et al. 1986, Melander, 
Staines, and Rokaeus 1986, Olpe and Steinmann 1991). Thus, we further verified 
correct expression of galanin-GFP by demonstrating their co-localization with 
tyrosine hydroxylase (TH), which we used as a marker for adrenergic neurons in 
the locus coeruleus (Figure 2.1, E).  We found that every galanin-GFP neuron co-
localized with TH.   
There are no known markers for galanin-expressing neurons in the exPFA. 
Thus instead, we stained brain sections from GalTgGFP mice with anti-galanin to 
detect galanin peptide as well as with anti-GFP to detect galanin-GFP expression 
(Figure 2.2). The overall expression pattern of galanin and galanin-GFP fibers was 
identical, but cell bodies could only be detected with galanin-GFP (Figure 2.2, A-C). 
Furthermore, confocal high magnification images convincingly showed that galanin-
positive fibers highly co-localized with galanin-GFP (Figure 2.2, D-F) in the PFA. 
These data indicate that galanin-GFP expression correctly corresponds with galanin 
neuropeptide expression; thus, verifying GalTgGFP mice as a useful tool to study 
galanin expressing neurons.  
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Figure 2.1 Similar expression patterns of galanin mRNA and galanin-GFP 
expression in the hypothalamus and locus coeruleus.  A., C.: In situ hybridization 
for galanin mRNA expression shows the distribution of galanin neurons in the 
hypothalamus (A.) and locus coeruleus (C.) of an adult mouse brain. Images were 
kindly provided by the Allen Brain Atlas Institute. B., C.: Immunohistochemical 
detection of galanin-GFP in GalTgGFP mice shows strong anatomical similarity to 
galanin mRNA expression with many galanin neurons in the hypothalamus (DMH, 
PFA and LH) (A. and B.) and the locus coeruleus (C. and D.). E. Double 
immunohistochemistry in GalTgGFP mice for galanin-GFP (green) and tyrosine 
hydroxylase (TH, red), a marker for adrenergic neurons, confirms the adrenergic 
character of galanin-GFP neurons in the locus coeruleus (E.). Note that galanin-
GFP also visualizes neuronal projections of galanin neurons, which are nicely 
visible in the pre-coeruleus that is void of galanin cell bodies.   
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Figure 2.2 Co-expression of galanin (peptide) and galanin-GFP in synaptic boutons 
of neuronal processes. Double immunohistochemistry in GalTgGFP mice for galanin-
GFP (green, A. and D.) and galanin peptide (red, B. and E.) shows similar 
distribution of neuronal processes in the DMH, PFA and LH (merge, C and F.). High 
magnification of the PFA under a confocal microscope (magnification is 63x, D. to 
F.) shows a complete overlap of galanin peptide containing synaptic boutons with 
galanin-GFP. Note, cell bodies are only visualized with galanin-GFP, but as 
expected not with galanin peptide. 
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  2.3.2 Distribution of galanin-expressing LepRb neurons.  The 
immunohistochemical detection of LepRb is difficult due to unspecific antibodies or 
lack of sensitivity. Leptin activates LepRb via the janus kinase-2/pSTAT3 signaling 
pathway, resulting in a robust induction of nuclear pSTAT3 that can be detected by 
western blotting as well as immunohistochemistry (Faouzi et al. 2007, Munzberg, 
Flier, and Bjorbaek 2004, Munzberg et al. 2003). We used LepRbGFP reporter mice 
to demonstrate that LepRb neurons show no pSTAT3 signal when injected with 
PBS (Figure 2.3, A), while an i.p. injection with 5 mg/kg leptin for 1h resulted in a 
robust induction of nuclear pSTAT3 that highly co-localized with LepRbGFP neurons 
(Figure 2.3, B). We further confirmed earlier findings that leptin-induced pSTAT3 
co-localizes with about 80% of LepRbGFP neurons {Figure 2.3, C; (Leinninger et al. 
2009, Zhang et al. 2011)}, demonstrating that leptin-induced pSTAT3 is highly 
representative for LepRb neurons. 
Galanin-GFP neurons are densely packed in the DMH, however, surprisingly 
only a small subpopulation in the ventral portion of the DMH (vDMH, Figure 2.4, A) 
co-expressed leptin-induced pSTAT3, marking LepRb-expressing neurons (galanin-
GFP/pSTAT3 neurons). The majority of galanin-GFP/pSTAT3 neurons were located 
in the perifornical area and lateral hypothalamus, where about 20-44%, 
respectively, of all pSTAT3 neurons are co-localized with galanin-GFP (Figure 2.4, 
A; Figure 2.5, A; Figure 2.6, B), and 17-28%, respectively, of all galanin-GFP 
neurons were co-localized with pSTAT3 (Figure 2.4, A; Figure 2.5, A; Figure 2.6, 
B).  Another significant population of galanin-GFP/pSTAT3 neurons was found in 
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the nucleus of the solitary tract; here about 25% of all pSTAT3 neurons co-
expressed galanin (Figure 2.4, B and Figure 2.5, B).  
We also carefully examined galanin-GFP neurons in the arcuate nucleus for 
potential co-localization with leptin-induced pSTAT3. Even though we found an 
occasional co-localization of galanin and pSTAT3, this was negligible compared to 
the large number of LepRb neurons found in the ARC (Figure 2.4, C).  In Figure 2.5 
the rostro-caudal distribution of galanin-GFP/pSTAT3 neurons in the hypothalamus 
(Figure 2.5, A) and brainstem (Figure 2.5, B) are shown. 
 
Figure 2.3 Leptin-induced pSTAT3 is a marker for LepRb neurons. LepRbGFP 
reporter mice were treated with PBS (A.) or leptin (1 mg/kg body weight, B.) for 1 
hour and fixed brain sections were stained for pSTAT3 (red) and GFP (green). C. 
Cell counts of double-labeled pSTAT3/LepRbGFP neurons in leptin treated LepRbGFP 
mice (n=2) to demonstrate that the majority of leptin-induced pSTAT3 highly 
correlates with LepRbGFP expression.  
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Figure 2.4 Immunohistochemical detection of Gal-LepRb neurons. Brain sections 
from transgenic GalTgGFP reporter mice were stained with double 
immunohistochemistry for Galanin-GFP (green) and leptin-induced pSTAT3 (red). 
A. Representative image of the exPFA depicting double labeled Gal-LepRb neurons 
in the PFA (inset top left), ventral DMH (vDMH, inset top middle) and lack of Gal-
LepRb neurons in the dorsal DMH (dDMH, inset top right). B. Representative image 
of the NTS with inset showing several Gal-LepRb neurons. C. Representative 
image of the ARC depicting some of the few Gal-LepRb neurons. Scale bars: A. 
200 µm; B. and C. 100 µm  
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Figure 2.5 Distribution of Gal-LepRb neurons. Rostro-caudal distribution of LepRb 
neurons (green, pSTAT3) and Gal-LepRb neurons (red, pSTAT3/galanin-GFP) in 
the exPFA (A.) and NTS (B.) relative to Bregma. 
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Figure 2.6 Quantification of galanin/pSTAT3 neurons in the exPFA. A. Number of 
galanin/pSTAT3 neurons compared to the total galanin or total pSTAT3 neurons in 
the exPFA (DMH, PFA, LH) (n=3). B. Percentage of galanin/pSTAT3 neurons 
based on total galanin or total pSTAT3 neurons in the exPFA (DMH, PFA, LH) 
(n=3). 
 
2.3.3 Neuropeptidergic characterization of galanin-GFP/pSTAT3 
neurons.  Within the lateral hypothalamus orexin and melanin-concentrating 
hormone (MCH)-expressing neurons are two well-characterized neuronal 
populations that are both known to regulate energy homeostasis. However, neither 
galanin- nor LepRb-expressing neurons were co-localized with orexin (Figure 2.7, 
A) or MCH (Figure 2.7, B).  Thus, galanin-GFP/pSTAT3 neurons are a distinct 
population from orexin and MCH neurons.  
Cocaine-and-amphetamine-regulated-transcript (CART)-expressing 
neurons are well known in the ARC where they are co-expressed with POMC-
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expressing neurons and are well known as anorexigenic neurons. Another CART 
population is found in the lateral hypothalamus and we found that about 56±1.2% 
(n=3) of all galanin-GFP/pSTAT3 neurons in the hypothalamus co-express CART 
(Figure 2.7, C and Figure 2.8, A). 
Leinninger et. al. (2009) showed recently that a large portion of LH LepRb 
neurons (about 60% of all LH LepRb neurons) co-express the anorexigenic 
neuropeptide neurotensin.  Therefore we wanted to investigate if galanin-
GFP/pSTAT3 neurons would also co-express neurotensin. Indeed, most 
identified neurotensin neurons were co-localized with galanin (about 95±3% of 
all neurotensin neurons, n=2; Figure 2.7, D and Figure 2.8, B). 
Neurotensin/galanin co-localization was restricted to the perifornical area and 
LH, suggesting that the neurotensin-LepRb neurons, identified by Leinninger et. 
al. (2009) may indeed represent galanin-GFP/pSTAT3 neurons 
(galanin/neurotensin-LepRb neurons). However, neurotensin neurons were not 
found in the DMH and the few neurotensin neurons in the NTS rarely co-
localized with galanin (Figure 2.7, E), suggesting that a subpopulation of 
galanin-GFP/pSTAT3 neurons is distinct from neurotensin-LepRb neurons.  
 Also, many galanin neurons in the LH did not co-localize with 
neurotensin. Because we were not able to study co-expression of galanin, 
neurotensin and LepRb neurons together (colchicine treatment distorts cell 
signaling events like STAT3 phosphorylation), we cannot entirely rule out that 
galanin-GFP/neurotensin neurons may specifically not express LepRb.  
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Figure 2.7 Gal-LepRb neurons in the exPFA are distinct from orexin and MCH 
neurons, but co-express CART and neurotensin. A-C (overviews) and a-c 
(magnified): GalTgGFP mice were treated 1h with leptin for detection of leptin receptor 
neurons via leptin-induced pSTAT3 (red, nuclear stain). Galanin-GFP is shown in 
green (A and B) or blue (C.) and sections were further stained for orexin (blue, A.), 
melanin concentrating hormone (blue, MCH, B.) or cocaine-and-amphetamine-
regulated transcript (green, CART, C.). D (overview) and d (magnified): Colchicine 
treated GalTgGFP brain sections were co-stained for galanin (green, GFP) and 
neurotensin (red). Scale bar A-D: 200 µm E: Brainstem section of the colchicine 
treated GalTgGFP brain co-stained for galanin (green, GFP) and neurotensin (red). 
Scale bar E.: 100 µm 
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Figure 2.8 Quantification of CART and neurotensin neurons. A. Cell counts of total 
Gal/pSTAT3 neurons in the exPFA and compared to Gal/pSTAT3 neurons that also 
co-express the neuropeptide CART (n=3). B. Cell counts of total neurotensin 
neurons and neurotensin neurons that also co-express galanin (n=1). 
 
2.3.4 Leptin increases exPFA galanin gene expression. We further tested 
if leptin may modulate galanin gene expression specifically in the exPFA. We 
compared the exPFA of chow fed ob/ob mice treated with either PBS or leptin over 
3 days and indeed found that leptin treatment caused a moderate, but significant 
increase in gene expression of galanin (p<0.005, Figure 2.9, A). To confirm correct 
leptin stimulation we compared SOCS3 expression in the exPFA and ARC of PBS 
and leptin treated mice. Indeed leptin induced SOCS3 expression in the ARC 
(p<0.01, Figure 2.9, C) and exPFA, even though in the exPFA data did not reach 
significance (p=0.07, Figure 2.9, B).  
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Figure 2.9 Leptin induces exPFA galanin gene expression. Relative gene 
expression of galanin (A.) and SOCS3 (B and C.) in the exPFA (A. and B.) and 
arcuate nucleus (C.) of ob/ob mice treated twice daily with either PBS or leptin 
(1mg/kg BW) over 3 days (n=6 per group). *pt-test<0.02 
 
2.3.5 Leptin stimulates exPFA LepRb neurons. Leptin can cause either a 
stimulation or inhibition of neuronal activity (Belgardt and Bruning 2010, Cowley et 
al. 2001, Munzberg et al. 2007), even though LepRb neurons in the LH have been 
mainly associated with stimulatory leptin action (Leinninger et al. 2009). Thus, we 
wanted to test if we could recapitulate leptin stimulation of LepRb neurons in all 
subdivisions of the exPFA, including the DMH, PFA and LH (Figure 2.10, p<0.03). 
We injected LepRbGFP reporter mice with PBS or leptin, perfused brains were 
harvested 3 hours later. After IHC staining the number of LepRb neurons that were 
co-expressed with cFos as a surrogate for neuronal activity were quantified. As 
expected, we found that leptin stimulates LepRb neurons in all subdivisions of the 
exPFA (DMH, PFA and LH). Leptin stimulated cFos was found in about 30-35% of 
all LepRb neurons (Figure 2.10), thus indicating that leptin may also stimulate 
neuronal activity in galanin-GFP/pSTAT3 neurons.  
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2.3.6 The exPFA is sufficient for anorexigenic leptin action. Given the 
mixed neuropeptide expression of anorexigenic and orexigenic neuropeptides in 
galanin-GFP/pSTAT3 neurons, combined with a likely neuronal stimulation of 
galanin-GFP/pSTAT3 neurons, we wanted to confirm that leptin action in the 
perifornical area (PFA), where the majority of galanin-GFP/pSTAT3 neurons are 
found, indeed results in anorexia. Thus, we injected low leptin doses (20 ng and 1 
ng) unilaterally into the PFA of GalTgGFP and C57B6 wildtype mice. 
We confirmed that PFA leptin is sufficient to decrease body weight and 
induce anorexia in GalTgGFP mice (Figure 2.11, A-C) and C57B6 mice (data not 
shown). Both doses, 20 ng (data not shown) and 1 ng leptin (Figure 2.11, A-C) 
were found effective to reduce body weight (Figure 2.11, A; pANOVA<0.01, pHolm-Sidak 
*<0.05), 24h food intake (Figure 2.11, B; pt-test<0.05) as well as respiratory 
exchange rate (RER, Figure 2.10, C; pANOVA<0.05, pHolm-Sidak *<0.05), even though 
1ng leptin was ineffective in C57B6 mice, likely due to differences in leptin 
sensitivity of the background strain (C57B6 versus GalTgGFP mice on an FVB 
background). 
Cannula placements in C57B6 (blue dots) and GalTgGFP (red dots) mice 
are shown schematically in Figure 2.11, D and cases of misplaced cannulas (see 
arrow in Figure 2.11, D) were removed from analysis. Figure 2.11, E shows an 
example of a cannula track in a GalTgGFP mouse using galanin IHC as landmark 
to show correct targeting of the fornix. Thus, we show that leptin action in the 
PFA, including galanin-GFP/pSTAT3 neurons, is sufficient to mediate 
anorexigenic leptin action in wildtype mice. 
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Figure 2.10 Leptin stimulates neuronal activity in exPFA LepRb neurons. LepRbGFP 
reporter mice were treated once with leptin (5mg/kg BW, n=3) for 3 hours to allow 
time for cFos induction as a surrogate for neuronal activation. The number of cFos 
labeled LepRb neurons was estimated by cell counts and reported as percent of 
total LepRb neurons (A.). The total number of LepRb (B.) neurons was also 
determined to ensure comparison of similar neuronal populations. pt-test<0.03.   
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Figure 2.11 Leptin mediates anorexigenic leptin action via the exPFA. A. Body 
weight of GalTgGFP mice before and after a single, unilateral injection of either 
PBS (n=4) or leptin (1 ng, n=3) into the exPFA. pANOVA<0.01, pHolm-Sidak *<0.05 B. 
Food intake of GalTgGFP mice over 24h after receiving a single, unilateral PBS or 
leptin (1 ng) injection. pt-test<0.05 C. Respiratory exchange ratio (RER) of 
GalTgGFP mice over 24 h after receiving a single, unilateral PBS or leptin (1 ng) 
injection; pANOVA<0.05, pHolm-Sidak *<0.05 D. Schematic drawing of cannula 
placements in GalTgGFP reporter mice and C57B6 mice. E. Representative 
injection site of a GalTgGFP reporter mouse stained for GFP to visualize 
anatomical landmarks such as DMH and fornix. Scale bar: 500µm   
 
2.4 DISCUSSION 
The aim of this study was to reinvestigate the existence and localization of 
LepRb neurons that co-express the neuropeptide galanin, which would characterize 
a new subgroup of LepRb neurons and would enable future molecular genetic 
studies to identify the importance of such a LepRb subpopulation for physiologic 
leptin action.  
Here, we show convincing evidence that galanin-GFP/pSTAT3 neurons are 
found in two distinct brain locations, one in the hypothalamus and another in the  
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brainstem. Leptin-induced pSTAT3 is an excellent marker of LepRb expressing 
neurons within the exPFA (DMH, PFA and LH), as shown in Figure 2.3 and earlier 
publications (Leinninger et al. 2009, Zhang et al. 2011), thus in the remaining 
discussion we will refer to galanin-GFP/pSTAT3 neurons simply as Gal-LepRb 
neurons.   
Galanin is well known to induce food intake, thus, it is possible that galanin 
would not only serve as a genetic marker for a subset of LepRb neurons, but 
galanin release from Gal-LepRb neurons could also play a role to mediate 
physiological leptin actions on food intake. Surprisingly, our data support that leptin 
induces exPFA galanin expression and stimulates neuronal activity in exPFA 
LepRb neurons, conflicting with an orexigenic action of galanin in this neuronal 
population. We found that Gal-LepRb neurons further co-localize with anorexigenic 
neuropeptides like neurotensin or cocaine-and-amphetamine-regulated-transcript 
(CART) and intra-exPFA leptin clearly mediated anorexia and weight loss.  
2.4.1 Technical considerations. We demonstrate that LepRb neurons co-
express the neuropeptide galanin in two distinct populations found within the 
hypothalamus and brainstem. Similar to an earlier double in situ hybridization study 
that focused on co-expression within the ARC and DMH, we found no or only 
sporadic co-localization in the ARC and only a low percentage of co-localization in 
the DMH (Cheung et al. 2001). But our data contradict previous reports that showed 
extensive co-localization (60% of all hypothalamic LepRb neurons) in the mouse or 
ewe (Hakansson et al. 1999, Iqbal et al. 2001). We hypothesized that these 
discrepancies are due to different methods used that may have lacked specificity 
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{LepRb IHC, (Hakansson et al. 1999, Iqbal et al. 2001)}. This is also supported by 
the fact that extensive co-localization of LepRb with MCH and orexin was reported 
(Hakansson et al. 1999, Iqbal et al. 2001). In contrast, our data (using leptin-
induced pSTAT3) did not support any co-localization of LepRb with MCH or orexin, 
which is consistent with earlier published data (Leinninger et al. 2009). Thus, our 
data show convincingly that leptin can directly act on galanin neurons in the exPFA 
and the nucleus of the solitary tract in the brainstem.  Furthermore, we identified 
that LepRb and galanin neurons are distinct from orexin and MCH neurons.   
2.4.2 LepRb neurons in the brainstem and lateral hypothalamus. LepRb 
neurons in the brainstem and lateral hypothalamus (LH) both contribute to the 
regulation of energy homeostasis (Leinninger et al. 2009, Hayes et al. 2010). 
However, the neuropeptides involved in these leptin actions have not been 
completely characterized. Within the LH, a subpopulation of LepRb neurons co-
expresses neurotensin (Leinninger et al. 2011). Our data show that exPFA 
neurotensin neurons almost entirely co-expressed galanin, even though compared 
to the total number of galanin neurons, neurotensin was only found in a small 
subset of galanin neurons. Thus, we conclude that the recently described 
population of neurotensin-LepRb neurons likely co-expresses galanin, even though 
technical limitations prevented us from specifically studying if Gal-LepRb neurons 
co-express neurotensin. Importantly, a subset of Gal-LepRb neurons (at least in the 
DMH and NTS) clearly does not co-express neurotensin.  
Instead, we found that half of all exPFA Gal-LepRb neurons co-expressed 
the neuropeptide CART, suggesting a heterogeneous character of Gal-LepRb 
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neurons. Surprisingly, we found combined expression of typical anorexigenic 
(neurotensin, CART) and orexigenic (galanin) neuropeptides, thus conflicting with 
the classic model of orexigenic or anorexigenic neurons (Schwartz et al. 2000).    
Within the exPFA, only LH LepRb neurons have been studied in more detail 
(Leinninger et al. 2009, Leinninger et al. 2011, Louis et al. 2010), characterized as 
the population distal-lateral to the fornix (Harris, Wimmer, and Aston-Jones 2005, 
Leinninger et al. 2009), thus excluding neurons in the perifornical area (PFA, 
surrounding the fornix) and dorsomedial hypothalamus (DMH, proximal-lateral to 
the fornix).  LH LepRb neurons are sufficient to regulate body weight and food 
intake in leptin-deficient ob/ob mice. Here we show that exPFA leptin administration 
is sufficient to decrease body weight and food intake even in wildtype mice.  Neither 
PFA nor DMH LepRb neurons have been studied in detail for their contribution to 
regulate energy homeostasis. Certainly, it will be necessary to further investigate 
the physiological importance of these specific Gal-LepRb populations for known 
leptin actions, such as food intake, energy expenditure and the rewarding value of 
food.  
2.4.3 Anorexic leptin action via inhibitory galanin action? To understand 
how leptin may regulate body weight and food intake in the exPFA, we tested if 
leptin would regulate the co-expressed neuropeptides. Galanin generally increases 
food intake (Kyrkouli et al. 1990), suggesting that anorexigenic leptin action should 
inhibit galanin expression or block galanin release. Surprisingly, we found that leptin 
upregulated galanin gene expression moderately, but significantly, in ob/ob mice. 
Furthermore, leptin stimulates neuronal activity in exPFA LepRb neurons, 
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suggesting that leptin induces galanin release. It is not plausible that anorexigenic 
leptin action requires increased expression and synaptic release of an orexigenic 
neuropeptide. Similarly, galanin neurons co-expressed the anorexigenic 
neuropeptides neurotensin and CART, again conflicting with an orexigenic galanin 
action.   
Galanin affects many biological systems from induction of food intake, 
reproduction to pain and addiction (Gundlach 2002, Hokfelt et al. 1999, 
Merchenthaler 2010, Picciotto 2010). Another prominent feature of galanin is its 
inhibitory action (Dong, Tyszkiewicz, and Fong 2006, Poulain, Decrocq, and 
Mitchell 2003, Xu, Zheng, and Hokfelt 2005). Interestingly, LH LepRb neurons are 
generally GABAergic (Leinninger et al. 2009), thus further supporting the known 
inhibitory leptin action on orexin neurons (Louis et al. 2010). Indeed, LH galanin 
injections had no orexigenic effects in rats (Kyrkouli et al. 1990). Thus, it is plausible 
to speculate that galanin acts as an inhibitory (instead of orexigenic) neuropeptide 
in Gal-LepRb neurons and that inhibitory galanin action plays an important role to 
mediate anorexigenic leptin action via the exPFA. Consistent with this, orexigenic 
galanin action has been attributed to galanin action with the PVN (Kyrkouli et al. 
1990, Menendez, Atrens, and Leibowitz 1992, Tempel, Leibowitz, and Leibowitz 
1988), while LH LepRb neurons do not project to the PVN, but rather project locally 
in the LH and to the VTA (Leinninger et al. 2009).  
2.4.4 Leptin regulation of exPFA galanin gene expression. A correlation 
of leptin and galanin gene expression has been studied by others with very 
inconsistent results, showing that leptin decreased galanin in the hypothalamus of 
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wildtype mice (Sahu 1998b, a), had no effect on galanin expression comparing 
leptin deficient ob/ob mice and wildtype mice (Williams et al. 1991) or increased 
galanin expression specifically in the periventricular region of leptin treated ob/ob 
mice (Cheung et al. 2001).  The presented results would support leptin induced 
gene expression in the exPFA, even though this was not a robust effect. exPFA 
galanin neurons may represent a heterogeneous neuronal population, that are co-
expressed with several neuropeptides with or without LepRb. Thus, leptin may 
regulate galanin expression differentially in subpopulations of galanin neurons. 
Furthermore, it needs to be cautioned that mRNA expression may not reflect the 
quantity of functional galanin at the synapses or the amount of galanin that is 
indeed released into the synaptic cleft. Therefore, changes in mRNA galanin 
expression may simply not correlate with changes in behavior. 
Leptin robustly stimulates cFos, a marker of neuronal activity, in exPFA 
LepRb neurons, suggesting increased neuropeptide release such as galanin. 
However, we could not determine if leptin-induced LepRb neurons indeed included 
Gal-LepRb neurons, and we cannot rule out that leptin may exclusively stimulate 
non-galanin LepRb neurons in the exPFA. Indeed, in the LH as well as other 
hypothalamic sites leptin exerts depolarizing and hyperpolarizing effects on 
individual LepRb populations (Cowley et al. 2001, Leinninger et al. 2009). Future 
studies are necessary to test if galanin indeed contributes to inhibitory leptin actions 
{e.g. inhibition of orexin neurons (Louis et al. 2010)} and to demonstrate how this 
affects anorexigenic leptin action.  
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The perifornical area and lateral hypothalamus are generally involved in 
reward behavior (Berthoud and Munzberg 2011) and regulate sleep and arousal via 
orexin neurons. Similarly, leptin (Fulton et al. 2006, Gaus et al. 2002, Laposky et al. 
2008, Laposky et al. 2006, Leinninger et al. 2009, Lu et al. 2002), galanin (Hawes 
et al. 2008, Picciotto 2010), neurotensin (Cape et al. 2000, Geisler et al. 2006, 
Hoebel 1985, Jones 2004) and CART (Jaworski et al. 2008, Keating et al. 2010, 
Philpot and Smith 2006) have all been associated with the control of reward as well 
as arousal behavior. Indeed, neurotensin-LepRb neurons modulate the reward 
system via orexin neurons. Even though it is still unknown by which mechanisms 
leptin inhibits orexin neurons (Louis et al. 2010). The fact that subpopulations of 
exPFA Gal-LepRb neurons also co-express neurotensin or CART suggests that 
Gal-LepRb neurons may be involved in the regulation of reward and arousal 
possibly via orexin neurons that could be inhibited by leptin induced galanin 
release.  
In summary, we present clear evidence that LepRb is expressed on galanin 
neurons in two distinct locations, one in the hypothalamus and another in the 
brainstem. Surprisingly, several Gal-LepRb neurons further co-localized with the 
anorexigenic neuropeptides neurotensin or CART. However, intra-exPFA leptin 
action clearly demonstrated that leptin mediates anorexia and body weight loss in 
the exPFA. Furthermore, leptin induced galanin gene expression in the exPFA of 
ob/ob mice, and induced neuronal activity in exPFA LepRb neurons, thus conflicting 
with an orexigenic galanin action in this system. Galanin has also been well known 
as an inhibitory neuropeptide (Dong, Tyszkiewicz, and Fong 2006, Poulain, 
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Decrocq, and Mitchell 2003, Xu, Zheng, and Hokfelt 2005), thus we speculate that 
galanin may act alternatively as an inhibitory neuropeptide, rather than an 
orexigenic neuropeptide in Gal-LepRb neurons. 
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CHAPTER 3.  LEPTIN REGULATES NUTRIENT REWARD VIA 
GALANIN NEURONS IN THE LATERAL HYPOTHALAMUS 
 
 
3.1 INTRODUCTION 
 
The rate of obesity is increasing worldwide (Mokdad et al. 2003), and this 
effect is likely due to the surplus and accessibility of calorically dense foods in 
modern societies.  Calorie-rich foods, namely those high in fat and sugar content, 
evoke a potent reward response when consumed. With the high availability of such 
rewarding foods it seems our current feeding behaviors have shifted from 
consuming nutrients solely for homeostatic survival purposes, to now eating foods 
based on the pleasure they evoke. Such alterations in nutrient selection behaviors 
that govern palatable food intake would indicate a mechanism currently driving the 
obesity epidemic.    
Leptin is highly implicated in obesity research as leptin signaling through 
LepRb exerts its anorexigenic effects via reductions in body fat mass and food 
intake. It is now appreciated that anorexic leptin actions are also mediated in part 
by leptin’s ability to modulate the rewarding value of food (Fulton et al. 2006). 
Reward behavior is regulated by the mesolimbic dopaminergic system, which 
consists of dopaminergic (DA) neurons in the ventral tegmental area (VTA) as well 
as their projection into the nucleus accumbens (NAc). In this circuit DA release 
modulates reward-motivated behaviors in response to a variety of stimuli 
(Hernandez and Hoebel 1988, Knutson et al. 2001, Ikemoto and Panksepp 1999, 
Nicola et al. 2005). The reward value of nutrients such as sucrose requires 
stimulation of midbrain DA neurons and is enhanced by fasting, whereas this effect 
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is abolished by central leptin action (Domingos et al. 2011).  Indeed, LepRbs are 
expressed on midbrain DA neurons and leptin directly inhibits these LepRb-DA 
neurons (Hommel et al. 2006). Conversely, leptin deficient ob/ob mice show 
reduced NAc DA content and peripheral or intra-LHA leptin rather increases NAc 
DA content (Leinninger et al. 2009, Fulton et al. 2006).  However, the exact 
neuronal circuits involved in stimulating DA release are not entirely clear.  
We previously reported on a large population of LepRb neurons in the LHA 
(referred to as exPFA in Chapter 2) that co-express the inhibitory acting 
neuropeptide galanin (Gal-LepRb neurons).  We also showed that LHA galanin 
expression was stimulated by leptin (findings reported in Chapter 2). Central 
galanin injections selectively increase fat intake, and deficiency in galanin or 
galanin-receptor-1 (GalR1) results in decreased dietary fat intake (Zorrilla et al. 
2007, Adams et al. 2008). Galanin also regulates reward circuits by inhibition of 
mesolimbic DA neurotransmission (Ericson and Ahlenius 1999, Counts et al. 2002), 
inhibition of noradrenergic LC neurons (Pieribone et al. 1995, Seutin et al. 1989, 
Sevcik, Finta, and Illes 1993) and counteracts withdrawal signs from abusive drugs 
(Zachariou et al. 2003).  Thus, we hypothesized that Gal-LepRb neurons may play 
a critical role in the regulation of nutrient reward and that this could be important for 
body weight regulation. To test this, we studied mice with conditional deletion of 
LepRb from galanin neurons (Gal-LepRbKO mice). Here we observed that disruption 
of leptin signaling in galanin neurons results in differential preferences for sucrose 
and Intralipid (fat emulsion solution) and causes increased body weight gain in the 
form of a late onset obesity phenotype. 
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3.2 MATERIALS AND METHODS 
3.2.1 Animals. All mice were bred and housed in a climate-controlled room 
(22C) on a 12-hour light/dark cycle with lights on at 7:00A.M. and lights off at 7:00 
P.M.  Food and water were available ad libitum unless otherwise specified.  All 
experimental protocols were approved by the Institutional Animal Care and Use 
Committee at the Pennington Biomedical Research Center. 
Generation of GalCre mice: An IRES-cre sequence was inserted into the 3’ 
end sequence encoding the murine galanin gene between the STOP codon and 
polyadenylation site; and a frt-flanked neo cassette was inserted downstream of the 
polyadenylation sites.  The construct was electroporated into mouse ES cells 
(albino C57B6 background), screening for construct insertion and injection into 
C57B6 blastocysts to generate chimeras was performed by the institutional 
transgenic core facility. Chimeras were bred to C57B6 mice and coat color 
screening was used to determine germline transmission. Correct genotypes were 
further confirmed by PCR, initially using long, transgene over-spanning DNA 
products to ensure correct insertion into the genome.   
Generation of Gal-LepRbKO mice: GalCre mice were further crossed with 
LepRbfl/fl mice on the mixed background C57BL/6J, FVB background {(McMinn et 
al. 2004) and kindly provided by Dr. Streamson Chua, Albert Einstein College of 
Medicine}, which generated Galcre/+; LepRbfl/+ and LepRbfl/+ mice. Final breeding 
pairs consisted of Galcre/+; LepRbfl/+ and LepRbfl/fl mice to generate control, wildtype 
(WT) LepRbfl/fl mice and Gal-LepRbKO mice Galcre/+; LepRbfl/fl mice or Galcre/cre; 
LepRbfl/fl mice.  
	  	   51 
Some GalCre experimental animals were further bred on the (B6.129X1-
Gt(ROSA)26Sortm1(EYFP)Cos/J background (stock#006148)(GalYFP reporter mice) and 
compared to transgenic GalTgGFP mice, which we used earlier to identify and 
characterize Gal-LepRb neurons in the LHA (as described in Chapter 2). In some 
mice the frt-flanked neo cassette was removed from the genome by crossing GalYFP 
mice with 129S4/SvJaeSor-Gt(ROSA)26Sortm1(FLP1)Dym/J mice (stock#003946)(Gal(-
neo)YFP reporter mice) to prove that reporter expression pattern was not 
compromised by the presence of the neo cassette.  
Genotyping of experimental animals was performed by PCR assessing 
hetero- or homozygous presence of GalCre{(cre forward: CCT CTC CCA AGC GGC 
CGG AGA ACC, cre reverse: CCG GCT CCG TTC TTT GGT GGC CCC TTC 
GCG,);	  wt-cre primers:  5’-TCC TGA GAC CAT GTC CAC TG (fwd), 5’-CTG CCA 
CTC CTG TGA TCT GA (rev)} and Leprfl (mLepr106: GTC TGA TTT GAT AGA 
TGG TCT T, mLepr105: ACA GGC TTG AGA ACA TGA ACA, mLepr65A: AGA 
ATG AAA AAG TTG TTT TGG). We used the latter primers also to screen for 
potential germline LepRb excision and such animals were excluded from the study.  
3.2.2 Metabolic phenotyping. Male Gal-LepRbKO and WT mice (n=11-15) 
were weaned into a multi-housing environment at three weeks of age and given 
standard rodent chow ad libitum (Laboratory Rodent Diet 5001, Purina).  Mice were 
individually housed at 4 weeks of age, food intake and body weight was measured 
weekly until twelve weeks of age and body weight gain was determined from 4-12 
weeks of age.  At 12 weeks of age body composition was determined by nuclear 
magnetic resonance (NMR; minispec-mq series Bruker Billerica, MA) before mice 
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were acclimated to the Comprehensive Laboratory Animal Monitoring System 
(CLAMS, Columbus Instruments, Ohio) for 3 days. Energy expenditure and 
locomotor activity was monitored continuously over 4 days.  In another cohort of 
aged 7-9 month old, male Gal-LepRbKO and WT littermates (n=7) body weight was 
again evaluated. Differences between groups were statistically analyzed with a 
repeated measure 2-way ANOVA or a Student’s t-test.  
3.2.3 Microdissection and qPCR. To determine differences in galanin and 
galanin receptor expression in the LHA,	  Gal-LepRbKO and WT mice (n=10-13) 
underwent CO2 asphyxiation before decapitation. Brains were rapidly removed and 
placed in a pre-cooled rodent brain matrix for mice consisting of 1mm, coronal 
dividers (Electron Microscopy Sciences, Hatfield, PA). After initial brain extraction, 
the rest of the microdissection procedure was conducted over ice. Ice-cold razor 
blades were used to cut 1mm thick brain sections in a rostral to caudal manner. 
Visual landmarks such as the mammillothalamic tract (mt), fornix (fx), and the 
anterior cinglulate area (aca) were used to strategically dissect the LHA and the 
NAc (refer to the schematic in Figure 3.1) from coronal brain slices. LHA tissue 
(LHA 1 and LHA 2) pieces were combined and collected in 1.5mL centrifuge tubes, 
flash frozen in dry ice, and stored in -80°C until further processed. 
RNA extraction, RT-PCR and qPCR procedures were previously described 
in Chapter 2. cDNA (10.5ng/reaction) was analyzed in triplicate via quantitative 
PCR for GAPDH (housekeeping gene; Mm99999915_g1), Galanin (Mm01236508), 
GalR1 (Mm00433515), GalR2 (Mm00726392), and GalR3 (Mm00443617;  TaqMan 
Universal PCR Master Mix; Applied Biosystems-4304437, Carlsbad, CA) using an 
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Applied Biosystems 7500 Real-Time PCR System. Fold induction of gene 
expression was calculated using the ΔΔCT method as described in Chapter 2. 
 
 
Figure 3.1 Dissection of the LHA and NAc based on visual anatomical landmarks. 
Red lines indicate cuts made for consistent tissue dissection as determined by 
visual landmarks. A. Dissection of the NAc (0.98mm from Bregma), using the aca to 
make a horizontal cut, followed by two lateral cuts to remove remaining cortex 
structures. B-C. Dissection of the LHA rostral (B. -1.22mm from Bregma) to caudal 
sections (C. -2.06mm from Bregma). The first cuts were made horizontally through 
the mt and the fx to separate LHA (1) and LHA (2). Next, vertical cuts through the fx 
separated LHA tissue from other hypothalamic structures (DMH, VMH, and ARC). 
Final cuts were made laterally to remove any remaining cortex/amygdala structures. 
 
 
3.2.4 Test for nutrient preference and reward. To test if WT and Gal-
LepRbKO mice like fat similarly, we offered a fat emulsion (10% Intralipid) for 1 hour 
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per day over 10 days in a single bottle to both genotypes to compare their 
cumulative fat intake. To assess their preferences for different palatable foods we 
further compared their intake of isocaloric solutions of sucrose (25% sucrose) and 
Intralipid (10%) in a two-bottle-choice test. Mice were allowed to consume either 
solution (water was removed) for 1 hour over 10 days, and bottle positions were 
alternated every other day to prevent side preferences. Statistical differences were 
analyzed via 3-way repeated-measure ANOVA, followed by a post-hoc analysis to 
analyze consumption over time or by 3-way ANOVA to compare absolute intake 
after 10 days or during the first 4 days of experiment.  
To analyze food-motivated/ reward-seeking behavior, mice were trained to 
run down a continually lengthening runway to reach a goal box containing a sweet 
treat (fruit loop), which is known as “incentive runway” (Pecina et al. 2003). Briefly, 
mice were maintained on a restricted feeding schedule (ad libitum food from 12:00-
4:00 P.M., food removed from 4:00-12:00 P.M.) to enhance training success. 
Prompting runway training, mice were allowed overnight access to fruit loops in 
their respective home cages to avoid any neophobic responses to the reward. The 
incentive runway training procedure was conducted in a staggered schedule, 
allowing mice one-day recovery between training sessions to reduce stress. There 
were a total of 13 training sessions, with each session consisting of 5 runway-
running trials (all sessions were conducted between 8:00 A.M. and 12:00 P.M., 
refer to schematic outlined in Figure 3.2). Sessions 1-3 were strictly acclimation 
trials, where the mice were granted access to the goal box with the fruit loop treat 
present. Runway training began on Session 4 and mice were placed at a starting 
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distance of 15 cm from the goal box.  With each subsequent session the runway 
length was increased in 15 cm increments until reaching a maximal distance of 75 
cm.  In all sessions, mice were allowed 30 seconds to consume the fruit loop after 
completion of the runway task.  Video footage of each session was recorded for 
slow motion analysis of running speed, number and duration of pauses, and 
reversals. 
 
 
Figure 3.2 Incentive runway measures reward-motivated behaviors. For runway 
running sessions mice were placed in enclosed start box (at the indicated distance 
from the goal box) for 30s.  The start box barrier was then removed and mice were 
able to enter the runway and proceed to the goal box containing the fruit loop 
reward (animals were allowed 30s to consume the reward after each trial). 
Completion speed was assessed as the time from which the animal entered the 
runway until entering the goal box. Sessions were conducted in a staggered 
schedule (1 day training, 1 day recovery), and each session consisted of 5 runway 
running trials 
 
3.2.5 Perfusions and immunohistochemistry. GalTgGFP, GalYFP, and Gal(-
neo)YFP mice and a separate cohort of Gal-LepRbKO and WT mice were all 
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administered a single leptin injection (5mg/kg, i.p.) and perfused exactly one our 
later.  Fixed brains were extracted post-fixed, and cryoprotected as described in 
detail in Chapter 2.  
Galanin-GFP expression comparison: To visualize Gal-LepRb neurons, brain 
sections were immunohistochemically processed as described in Chapter 2 for 
leptin-induced pSTAT3 (anti-pSTAT3, 1:1000; DAB) and successively 
counterstained for GFP (anti-GFP, 1:1000; fluorescent).  Sections were mounted 
onto gelatin-subbed slides and cover slipped with Pro-Long Anti-fade mounting 
medium (Invitrogen; Carlsbad, CA).  Galanin-GFP expression in the LHA and NTS 
of transgenic GalTgGFP mice (which was described earlier in Chapter 2) was used to 
identify and compare the distribution of Galanin-Cre driven GFP expression in 
GalYFP mice and Gal(-neo)YFP mice. Additionally, corresponding LHA and NTS 
sections from GalYFP and Gal(-neo)YFP mice were used to identify accurate leptin-
induced pSTAT3/ GFP co-expression (Gal-LepRb neurons), as those previously 
described in transgenic GalTgGFP mice.  
Confirmation of proper LepRb deletion in Gal-LepRbKO mice: LepRb-
expressing neurons were visualized via immunohistochemical procedures 
described in Chapter 2 for DAB labeling of leptin-induced pSTAT3 expression and 
further processed as described below. 
3.2.6 Estimate of cell counts. Microscopy imaging procedures have been 
previously described in Chapter 2. For quantification of leptin-induced pSTAT3 in 
the LHA and NTS brains from WT and Gal-LepRbKO mice (n=4-8 per genotype) that 
were treated with leptin for 1h were analyzed. For each area 2 sections containing 
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leptin-induced pSTAT3 were imaged using the Olympus BX51 bright-field 
microscope and Olympus DP30BW digital camera (Olympus; Center Valley, 
PA)(LHA=2 sections; NTS=2 sections).  pSTAT3 signals were amplified by 
appropriate changes in brightness and contrast, making sure that adjustments 
remained consistent between sections and animals. The number of pSTAT3 
positive cell nuclei was quantified and compared between groups with a Student’s t-
test. 
 
3.3 RESULTS 
 
3.3.1 Generation and validation of Gal-LepRbKO mice. In order to 
understand the physiological importance of leptin action in galanin neurons we 
aimed to delete LepRb selectively from galanin neurons. Thus, we generated mice 
that expressed cre-recombinase from the native galanin locus and crossed them 
with LepRbfl/fl mice {kindly provided by Dr. Streamson Chua: (McMinn et al. 2004)} 
to generate Gal-LepRbKO mice (GalCre/+; LepRbfl/fl or GalCre/Cre; LepRbfl/fl) and WT 
littermates (Gal+/+; LepRbfl/fl; mouse construct schematic Figure 3.3, A). For 
validation of correct cre-expression in GalCre mice GalYFP mice were generated by 
crossbreeding with cre-inducible YFP reporter mice (B6.129X1-
Gt(ROSA)26Sortm1(EYFP)Cos/J, stock#006148).  We compared GFP expressing 
neurons in transgenic GalTgGFP mice (Figure 3.3, left panels), which we described 
earlier in Chapter 2 to identify and characterize Gal-LepRb neurons in the LHA to 
GalYFP mice (middle panels) and Gal(-neo)YFP mice (right panels), where the frt-
flanked neo cassette was removed from the genome by crossing GalYFP mice with 
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mice that express flp-recombinase ubiquitously (129S4/SvJaeSor-
Gt(ROSA)26Sortm1(FLP1)Dym/J, stock#003946).  
The distribution of hypothalamic GalGFP neurons was very similar in all 
mouse models (Figure 3.3). We also confirmed that galanin neurons correctly 
expressed LepRb, by visualizing leptin-induced pSTAT3 with immunohistochemistry 
(IHC). As expected, pSTAT3 positive galanin neurons were found in the PFA, LH 
and to a lesser extent in the ventral portion of the DMH  (Figure 3.3, B) and another 
population was found in the NTS (Figure 3.3, C) in GalTgGFP, GalYFP and Gal(-neo)YFP 
mice. Galanin neurons with detectable leptin-induced pSTAT3 are further referred 
to as Gal-LepRb neurons. All remaining experiments were only performed with 
GalYFP mice.  
To confirm efficient deletion of LepRb in Gal-LepRbKO mice we compared 
leptin-induced pSTAT3 in Gal-LepRbKO and WT littermates. Leptin-induced pSTAT3 
was significantly decreased in the LHA and NTS, as seen in IHC images (Figure 
3.4, B) as well as by cell counts of pSTAT3 positive neurons (Figure 3.4, C-D; n=4-
5, p<0.01).  
3.3.2 Increased body weight gain in Gal-LepRbKO mice. To assess the 
metabolic phenotype of Gal-LepRbKO mice we followed their body weight and food 
intake over 12 weeks after weaning (4 weeks, n=10-12). Similar to leptin and leptin 
receptor deficient mice, Gal-LepRbKO mice show a significantly lower body weight 
compared to their WT littermates at 4 weeks of age (Figure 3.4, E; p<0.05). At 12 
weeks of age body weights were undistinguishable between both groups (Figure 
3.4, E). However, the body weight gain over 8 weeks was significantly increased in 
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Gal-LepRbKO mice compared to WT mice (Figure 3.4, F; p<0.05). Consistent with a 
slow but accumulating increase in body weight gain we found, in a separate cohort 
of aged (7-9 month old) mice, that Gal-LepRbKO mice were indeed significantly 
heavier than WT littermates (Figure 3.4, G; n=7-8, p<0.05). However, food intake 
(Figure 3.4, H), energy expenditure (Figure 3.4, I) or locomotor activity (Figure 3.4, 
J) could not be clearly attributed to these differences in body weight gain. 
 
Figure 3.3 Similar galanin-GFP expression between GalTgGFP, GalYFP and Gal(-
neo)YFP mice.  A-C. GFP expression in coronal brain sections of GalTgGFP mice (left 
panels) GalYFP mice (middle panels) and Gal(-neo)YFP mice where the frt-flanked neo 
cassette was removed (right panels). A. Hypothalamic expression GalGFP. 
Confirmation of galanin neurons (green) correctly expressing LepRb via 
visualization of leptin-induced pSTAT3 (red) in the LHA- B. and in the NTS- C. 
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Figure 3.4 Gal-LepRbKO mice experience late-onset obesity. A. Generation of Gal-
LepRbKO mice (GalCre/+; LepRbfl/fl or GalCre/Cre; LepRbfl/fl); mouse construct 
schematic. Confirmation of efficient deletion of LepRb in Gal-LepRbKO mice as 
visualized B. by leptin-induced pSTAT3 in Gal-LepRbKO (KO) and control (WT) 
littermates and quantified via total pSTAT3 cell counts in the LH. C.  Metabolic 
phenotyping was assessed via weekly body weight- E. and food intake- H. 
measurements over 12 weeks after weaning (4 weeks, n=10-12); where Gal-
LepRbKO mice showed a smaller weaning weight compared to WT mice (E.  
p<0.05), but no differences of body weight were observed at 12 weeks of age. The 
lower weaning weight translated into a significant increase of 8-week body weight 
gain in Gal-LepRbKO mice (F. p<0.05), and late-onset obesity was observed in 7-8 
month old Gal-LepRbKO mice (G. n=7-8, p<0.05).  No differences were observed in 
cumulative food intake (H. 4-12 weeks of age), energy expenditure (I. 12 weeks of 
age) or locomotor activity (J. 12 weeks of age). 
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3.3.3 Decreased LHA galanin signaling is associated with decreased fat 
intake. The inhibitory acting neuropeptide galanin has been shown to selectively 
modulate the ingestion of fat (Tempel, Leibowitz, and Leibowitz 1988) and we have 
shown earlier that leptin increases galanin expression in the LHA. Thus, we tested if 
lack of leptin action in Gal-LepRbKO mice similarly regulates gene expression of 
galanin or its receptors and if this would modulate fat ingestion. We analyzed 
mRNA expression in the LHA of WT and Gal-LepRbKO mice and found a 57% 
decrease in galanin expression (Figure 3.5, A; pt-test<0.01) and a 30% decrease in 
GalR1 expression (Figure 3.5, B; pt- test<0.05) within the LHA, while gene 
expression of all other galanin receptors (GalR2 and GalR3) were unchanged 
(Figure 3.5, B) 
Thus, we further tested if this affected their fat ingestion. Naïve Gal-LepRbKO 
mice and WT littermates had access to a 10% Intralipid (fat emulsion) solution for 1 
hour per day over 10 days. It had been reported by others that various 
concentrations of Intralipid solution are highly palatable for mice and the amount of 
Intralipid ingested correlates with the “liking” of the offered solution (Sclafani 2007). 
As expected, both WT and Gal-LepRbKO mice showed increasing Intralipid 
consumption over 10 consecutive 1-hour access sessions.  However, Gal-LepRbKO 
mice consumed significantly less Intralipid solution over the 10 days compared to 
WT mice (Figure 3.5, C; n=4-5; pANOVA<0.001; *pHolm-Sidak<0.05-0.001), indicating 
that they “liked” the Intralipid solution less than the WT mice.  
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Figure 3.5 Altered nutrient reward in Gal-LepRbKO mice. A. LHA galanin mRNA 
expression is decreased in Gal-LepRbKO mice (n=10-13, *pt-test<0.01). B. LHA 
galanin receptor 1 (GalR1) mRNA expression is decreased in Gal-LepRbKO mice 
(n=10-13, *pt-test<0.05). C. Cumulative Intralipid intake is reduced in Gal-LepRbKO 
mice during a 1 hour daily access of a single bottle of 10% Intralipid over a 10 
period (n=5; pANOVA<0.001; *pHolm-Sidak<0.05-0.001).  D. Cumulative sucrose intake is 
increased, but Intralipid intake is decreased in Gal-LepRbKO mice during a 1h daily 
two-bottle-choice access of isocaloric 10% Intralipid and 25% sucrose solutions 
(both 1 kcal/ml) over a 10 period (n=5-7; pANOVA<0.0001; *pHolm-Sidak<0.05-0.001). E. 
Comparison of total sucrose and Intralipid intake over 10 days shows a clear 
preference of sucrose over Intralipid in Gal-LepRbKO mice, while WT mice did not 
show preference for either solution (n=5-7, pANOVA<0.001; * pHolm-Sidak <0.01). F. 
Daily intake of sucrose and Intralipid during the first 4 days shows that sucrose 
preference is prevalent on day 1 in naïve Gal-LepRbKO mice (pANOVA<0.05; * pHolm-
Sidak <0.02). 
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Next we wanted to test if this behavior was selective for fat or if other 
palatable nutrients like sucrose were also less “liked.” In another cohort of naïve 
mice (n=6-9) we gave 1-hour daily access to a choice of isocaloric (1 kcal/ml) 
solutions of 25% sucrose and 10% Intralipid over 10 consecutive days. Again, Gal-
LepRbKO mice consumed less Intralipid compared to WT mice, but in striking 
contrast Gal-LepRbKO mice consumed more of the isocaloric sucrose solution 
compared to WT animals (Figure 3.5, D; n=6-9; pANOVA<0.0001; *pHolm-Sidak<0.05-
0.001). While WT mice ingested equal amounts of Intralipid and sucrose solutions 
and thus had no preference for either of the solutions, Gal-LepRbKO showed a 
robust and significant preference for sucrose over lipids (Figure 3.5, E; n=6-9, *pt-
test<0.05). Therefore, deficiency of LepRb in galanin neurons differentially 
modulates the preference for sucrose and lipids. Importantly, the robust sucrose 
preference in Gal-LepRbKO mice was present from the first day of exposure to the 
solutions (Figure 3.5, F; pANOVA<0.05; * pHolm-Sidak <0.02) demonstrating that this 
nutrient selection is not due to a learned behavior.  
3.3.4 Gal-LepRbKO mice work more for sugar rewards. We further wanted 
to evaluate if the increased sucrose preference observed in Gal-LepRbKO mice 
would also affect their motivation to work for a sucrose food reward; which has 
been also termed “wanting” (Berridge, Robinson, and Aldridge 2009). The incentive 
runway has been successfully used in mice to evaluate their motivation to work for 
food rewards (Pecina et al. 2003) and is particularly useful in mice due to the 
simplicity of the learning task. Mice were trained to run a straight path with 
increasing runway length (up to 75 cm) to obtain a visible food reward (fruit loop).  
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Various aspects of runway performance were analyzed to compare food-motivated 
behaviors between Gal-LepRbKO and WT mice respectively. 
Indeed, we found that Gal-LepRbKO mice showed an increased motivation to 
work for a sugary treat, which was observed as an increased completion speed to 
obtain the food reward (Figure 3.6, A; n=4; pANOVA<0.05; *pHolm-Sidak<0.05-0.02). 
Further analysis revealed that Gal-LepRbKO mice had more incidences of direct, 
undistracted runs, while WT mice spend significantly more time with distractions 
such as pauses, falters and reversals (Figure 3.6, B and C; n=4; pANOVA<0.05; pHolm-
Sidak<*0.03, #=0.06; pt-test<0.03, respectively). In addition, Gal-LepRbKO mice also ran 
faster to obtain the sugary treat compared to their WT littermates (Figure 3.6, D and 
E; n=4; pANOVA<0.03; pHolm-Sidak<*0.03, **<0.02, #=0.08; pt-test<0.03, respectively).  
 
3.4 DISCUSSION 
 
Our data demonstrate that LHA leptin action - via galanin neurons – indeed 
robustly regulates nutrient reward. Dysregulation of this system, by deletion of 
LepRb from galanin neurons, enhances body weight gain and causes late onset 
obesity; strongly suggesting that nutrient reward behavior drives body weight gain. 
The concept that galanin controls macronutrient selection has been first introduced 
by Leibowitz and colleagues, where they found that central galanin injections 
selectively increases fat intake, while carbohydrate intake remained unchanged 
(Tempel, Leibowitz, and Leibowitz 1988). More recently, galanin’s effect on fat 
intake was further supported in galanin deficient mice, which showed a decreased 
ingestion of a high fat diet (Adams et al. 2008).  
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Figure 3.6 Gal-LepRbKO mice work more for sugar rewards. In the incentive runway 
WT and Gal-LepRbKO mice (n=4 each genotype) were tested for their completion 
speed (cm/sec= runway length [cm] /time from leaving start box till entering goal 
box [sec]) (A.; pANOVA<0.05; *pHolm-Sidak<0.05-0.01).), the number of direct runs (in 
contrast to distracted runs) (B., C.; pANOVA<0.05; pHolm-Sidak<*0.03, #=0.06; pt-
test<0.03, respectively) and running speed (mean completion speed from all direct 
runs)(D., E.; pANOVA<0.03; pHolm-Sidak<*0.03, **<0.02, #=0.08; pt-test<0.03, 
respectively). Each session consisted of 5 trials and sessions that were held every 
other day.  
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Similarly, GalR1 deficient mice show a decreased ingestion of high fat diet, even 
though their short-term consumption was initially increased (Zorrilla et al. 2007). In 
line with this, our data demonstrate that reduced galanin and GalR1 mRNA 
expression in the LHA is associated with decreased fat (10% Intralipid) 
consumption, supporting the idea that galanin action in the LHA via GalR1 
importantly controls fat ingestion.  
On the contrary, we observed that Gal-LepRbKO mice exhibit a robust 
preference for sucrose over Intralipid, and even consumed significantly more than 
their WT littermates. Leptin deficiency in humans and rodents dramatically 
increases the rewarding value of all foods; which mimics the strong effect of fasting 
to enhance the rewarding value of food (Myers, Cowley, and Munzberg 2008). 
Reward is strongly influenced by midbrain dopamine (DA) neurons and optogenetic 
stimulation of DA neurons paired with water intake is strongly preferred over water 
without DA neuronal stimulation. However, DA stimulation alone is not able to 
override preferences for sucrose solutions (Domingos et al. 2011).  This nicely 
demonstrates the importance of the DA system for reward, while pointing out that 
food rewards such as sucrose require additional regulatory circuits. Sucrose 
consumption stimulates DA neurons and metabolic states can either enhance or 
abolish DA responses. Thus, fasting enhances sucrose preference over non-caloric 
sweeteners, while leptin abolishes this effect.  
Our data demonstrate that the robust sucrose preference further translates 
into enhanced work for a sweet treat. Gal-LepRbKO mice perform the incentive 
runway with increased running and completion speed, and show fewer distractions 
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during the task performance. Leptin action in the LHA regulates the mesolimbic DA 
system by direct LepRb projections to the VTA (Leinninger et al. 2009) as well as 
innervation of orexin neurons (Louis et al. 2010). Moreover, orexin neurons also 
innervate the VTA to regulate DA neurons (Korotkova et al. 2003). Indeed, 
peripheral leptin injections and intra-LHA leptin increases DA content in the NAc of 
ob/ob mice (Fulton et al. 2006, Leinninger et al. 2009). Similarly, orexin action in the 
VTA is known to stimulate DA release. However, leptin inhibits orexin neurons, 
which should decrease DA release in the NAc. Thus, determining the distinct circuit 
by which Gal-LepRb neurons mediate nutrient reward (either via projections to the 
VTA, orexin neurons etc.) may resolve some of these discrepancies encountered 
when LepRb function is generalized to the entire LHA-LepRb population.  
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CHAPTER 4: DEFINING GAL-LEPRB NEURONAL CIRCUIT: 
POTENTIAL SITES OF ACTION 
 
 
4.1 INTRODUCTION 
 
The lateral hypothalamus area (LHA) is a brain region well recognized for its 
role in reward function. Particularly, activation of LHA orexin neurons enhances 
reward-motivated behaviors, which is largely accomplished via orexin-induced 
stimulation of mesoaccumbal DA release. Palatable foods, high in sugar and fat, are 
perceived to be highly rewarding and generally evoke an increased motivational 
state to obtain them. And orexin mediates these reward responses as central orexin 
injections increase sucrose intake, while genetic or pharmacological blockade of 
orexin signaling decreases the rewarding value and intake of sucrose (Cason et al. 
2010).  Moreover, the activity of orexin neurons is highly correlated with sucrose 
seeking behaviors (Harris, Wimmer, and Aston-Jones 2005). Thus, the pathway 
responsible for negatively regulating orexin’s activity seems to be a crucial 
component in aspects of reward-based feeding and the development of obesity.  
The anorexigenic hormone leptin is a likely candidate for opposing orexin’s 
effects, as leptin treatment decreases the rewarding value of sucrose and attenuates 
sucrose seeking behaviors (Figlewicz et al. 2006, Figlewicz et al. 2001).  Moreover, 
leptin has been shown to inhibit the activity of orexin neurons, but how this is 
accomplished has not been determined. We do know that leptin is not capable of 
directly inhibiting orexin neurons, as we confirmed that LHA LepRb neurons are not 
co-expressed with orexin neurons {(Louis et al. 2010, Leinninger et al. 2009) and our 
data shown in Chapter 2}. LHA LepRb neurons were observed to innervate orexin 
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neurons (Leinninger et al. 2011, Louis et al. 2010), suggesting that leptin may 
indirectly inhibit orexin neurons to regulate nutrient reward.  Importantly our data 
shows that leptin modulates the reward value of nutrients via LHA Gal-LepRb 
neurons. We observed that mice exhibiting targeted LepRb deletion exclusively in 
galanin neurons (which we refer to as Gal-LepRbKO mice) exhibit a robust 
preference for sucrose over lipids.  Interestingly, Gal-LepRbKO mice demonstrated 
enhanced food-motivated behaviors for a sugary treat, indicative of increased orexin 
activity. 
In order to determine the precise pathway by which leptin signaling in Gal-
LepRb neurons modulates nutrient reward, we employed a cell-specific viral tracing 
method to study anterogradely-labeled neural projection sites specific to either 
galanin and LepRb neurons in the LHA. Here we show that Gal-LepRb neurons do, 
in fact, innervate local orexin neurons. In line our hypothesis that Gal-LepRb 
neurons mediate leptin’s inhibitory influence over orexin neurons, the absence of 
leptin signaling in galanin neurons (Gal-LepRbKO mice) translates into increased 
activation of orexin neurons.  Interestingly, Gal-LepRb neurons do not project to the 
VTA as previously reported for LHA-LepRb neurons, however, they were found to 
innervate the noradrenergic locus coeruleus (LC); a nucleus that had not been 
associated with leptin action. Importantly, our data demonstrates that Gal-LepRb 
neurons are a distinct LHA LepRb population that modulates the reward value of 
nutrients by eliciting an inhibitory tone onto orexin neurons. 
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4.2 MATERIALS AND METHODS 
 
4.2.1 Animals. All mice were bred and housed in a climate-controlled room 
(22C) on a 12-hour light/dark cycle with lights on at 7:00A.M. and lights off at 7:00 
P.M.  Food and water were available ad libitum unless otherwise specified.  All 
experimental protocols were approved by the Institutional Animal Care and Use 
Committee at the Pennington Biomedical Research Center. GalCre and LepRbCre 
mice (described in Chapter 2 and 3) were used for cre-driven/cell-specific 
expression of anterograde adeno-viral tracing experiments to investigate projection 
sites of Gal-LepRb neurons. GalYFP mice (described in Chapter 3) were used to 
identify the presence of retrogradely labeled Gal-LepRb neurons from the LC (to 
confirm adenoviral anterograde findings).  Finally, a cohort of Gal-LepRbKO mice 
and their WT littermates (described in Chapter 3) were used to assess potential 
differences in orexin gene expression and neuronal activity. 
4.2.2 Acute tracing studies. Adenoviral constructs: To define anterograde 
projections from galanin- and LepRb-expressing neurons in the LHA, we employed 
the use of molecular tracers with the cre-inducible system (for galanin- and LepRb-
specificity) and adenoviral stereotaxic injection (for anatomic specificity) using two 
adenoviral vectors, Ad-iz/EGFPf and Ad-iN/WED. For the generation of Ad-
iZ/EGFPf, the floxed β-geo cassette from pCALL was excised and inserted 
upstream of the MCS from pShuttleCMV (He et al. 1998) to generate pShuttle-iZ. 
The coding sequence of EGFP from pEGFP (Invitrogen) was amplified with the 
addition of sequences encoding a COOH-terminal farnesylation by standard PCR 
and subcloned into the MCS of pShuttle-iZ to generate pShuttle- iZ/EGFPf, which 
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was purified, linearized and utilized to generate the Ad-iZ/EGFPf adenovirus as 
previously described (Leshan et al. 2009, Leinninger et al. 2009). Ad-iZ/EGFPf 
results in cre-inducible expression of farnesylated EGFP to mark cell bodies and 
processes of cre-expressing neurons, while the viral injection spread can be 
monitored by β-galactosidase (β-gal) expression in non-cre expressing neurons. 
For the generation of the Ad-iN/WED construct, the β-gal-encoding region of the β-
geo fusion was deleted in pShuttle/iZ. Thus, generating pShuttle/iN, thereby 
decreasing the size of the construct to promote proper viral packaging with larger 
inserts. The coding region of WGA along with an IRES element and the coding 
sequence for farnesylated DsRed was then subcloned into the MCS of pShuttle/iN 
vector to generate pShuttle-iN/WED. Vector DNA was purified, linearized and 
utilized to generate the cre-inducible WGA adenoviral vector (Ad-iN/WED). Cre-
dependent WGA expression from Ad-iN/WED was verified in vitro by 
immunohistochemical staining for WGA in infected HEK293 cells transfected with a 
vector encoding cre recombinase as determine previously (Louis et al. 2010). Ad-
iN/WED results in cre-inducible expression of DsRed and wheat germ agglutinin 
(WGA). WGA is further anterogradely and transsynaptically transported into second 
order neurons, while DsRed remains in first order cre-expressing neurons.  
For surgical procedures of acute central injections mice were deeply 
anesthetized with 1-3% isofluorane/oxygen and the head was mounted on a 
stereotaxic frame (M1900 Stereotaxic alignment system, Kopf instruments, 
Tujunga, CA). The surgical area was prepared by shaving and sterilizing the scalp 
of the mouse with 70% ethanol and nolvassan. Ophthalmic ointment was next 
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applied to the animalʼs eyes to provide lubrication throughout the surgical 
procedure. Starting slightly behind the eyes, a midline sagittal incision about 2-3 cm 
long was made to expose the skull. Hydrogen peroxide was rubbed directly onto the 
skull to remove connective tissue and provide a means to adequately visualize and 
define Bregma. Bregma was then used as a reference point to determine the 
injection location for the stereotaxic coordinates of the LHA (X -0.9mm, Y -1.3mm, Z 
-5.2mm from Bregma) in GalCre and LepRbCre mice, or the LC (X -0.8, Y -5.4, Z -
3.7mm from Bregma) in GalYFP mice. An access hole was drilled to insert the guide 
cannula. A stainless steel guide cannula with dummy (Plastics One, Roanoke, VA) 
was lowered to the appropriate depth, and the injector was loaded with the 
respective tracing agent using a 0.5ul Hamilton syringe (Hamilton, Reno, NV). The 
filled injector was then inserted into the guide cannula and tracers were infused into 
the respective brain areas at a rate of 10nl/20s.  
For galanin and LepRb adenoviral anterograde tracing experiments, GalCre 
and LepRbCre mice received a LHA-targeted injection of either the Ad-iZ/EGFPf or 
Ad-iN/WED adenovirus (250-350nl, 2-6x1012 PFU/ml). After the infusion was 
complete, the injector was removed, the hole filled with bone wax and skin was 
closed with wound clips. Mice were subcutaneously administered the analgesic, 
Carprofen (10 mg/kg: two injections within 24 hours of surgery), and administered 
an injection localized to the incision of Buvidiocaine/Lidocaine mixture (2.5 mg/kg). 
Mice were allowed to recover on a heating pad and then single-housed in a 
biohazard containment room.  After 7-10 days incubation time, mice were perfused, 
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fixed brains were extracted, cryoprotected (as described in Chapter 2) and 
processed for immunohistochemical analysis as described.  
For injection of the non-specific retrograde tracer (FG), the cannula was 
inserted into the LC (based on above coordinates) of GalYFP mice and 10nl of a 
2%FG solution was injected over 20 seconds. The injector was then removed, the 
hole filled with bone wax and skin was closed with wound clips. Mice were 
subcutaneously administered the analgesic, Carprofen (10 mg/kg: two injections 
within 24 hours of surgery), and administered an injection, localized to the incision, 
of Buvidiocaine/Lidocaine mixture (2.5 mg/kg). Mice were allowed to recover on a 
heating pad and then single-housed in clean cages. 3-5 days post-injection, 
animals were administered a single i.p. leptin injection (as described below) and 
perfused exactly 1 hour later.  Fixed brains were extracted, cryoprotected (as 
described in Chapter 2) and processed for immunohistochemical analysis.  
4.2.3 Immunohistochemistry. Refer to page xi for detailed primary antibody 
information, and Chapter 2 for DAB and fluorescent immunohistochemical detection 
methods. For Ad-iZ/EGFPf axonal tracing experiments, detection of cre-inducible 
fluorescent expression of the farnesylated enhanced green fluorescent protein 
(EGFPf; detected via anti-GFP antibody 1:1000) was used for visualization of 
anterogradely labeled axon fibers from LHA galanin and LepRb neurons. The 
extent of viral spread in the LHA was immunohistochemically detected via non-cre 
specific β-gal expression (Ad-iZ/EGFPf; anti- β-gal, 1:1000).   
For Ad-iN/WED neuronal tracing experiments, detection of cre-inducible 
fluorescent expression of DsRed (anti-DsRed, 1:1000) was used for visualization of 
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primary (cre-expressing) galanin and LepRb neurons, whereas fluorescent 
detection of WGA (detected via anti-GFP antibody, 1:1000) allowed the 
visualization of both primary and second order (synaptically coupled) neurons from 
LHA galanin and LepRb neurons. Further, we determined that LHA galanin neurons 
innervate the adrenergic neurons of the LC via neuronal co-expression of galanin-
derived WGA and tyrosine hydroxylase (anti-TH, 1:1000) within the LC.   
Leptin-induced STAT3 phosphorylation: Detection of leptin receptors was 
visualized via phosphorylation of the downstream leptin signaling transcription 
factor STAT3.  To assess if Gal-LepRb neurons, specifically, innervate the LC, 
GalYFP mice were injected with the retrograde tracer FG targeted to the LC as 
described above. 3-5 days following, mice were injected with 5-mg/kg dose of leptin 
(i.p.). Precisely 1 hour after leptin treatment, animals were perfused for brain 
fixation. GalYFP mice were confirmed for accurate LC-targeted FG injections (n=2) 
via fluorescent FG (anti-FG, 1:1000) expression in the LC. In the LHA, 
immunohistochemical detection of triple labeled neurons positive for leptin-induced 
pSTAT3 (anti-pSTAT3, 1:1000; detected via DAB), FG (anti-FG, 1:1000; 
fluorescently labeled) and GFP (anti-GFP, 1:1000; fluorescently labeled) confirmed 
this projection.  
To assess differences in baseline activation of orexin neurons in Gal-
LepRbKO and WT mice, brain sections were co-stained for orexin-A (anti-orexin, 
1:1000; fluorescently detected) and nuclear cFos (anti-cFos, 1:3000; DAB 
detection).  Neurons co-expressing cFos and orexin are indicative of an activated 
orexin neuron. Sections were mounted onto gelatin-subbed slides and cover 
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slipped with Pro-Long Anti-fade mounting medium (Invitrogen; Carlsbad, CA) for 
further microscopy analysis described below.  
4.2.4 Estimate of cell counts. Microscopy procedures have been previously 
described in Chapter 2. For quantification of baseline activity of orexin neurons, 
brain sections of WT and Gal-LepRbKO mice (n=5) were analyzed for cFos/orexin 
co-expression. Four sections containing the entire population of LHA orexin 
neurons were identified for each animal and organized anatomically in a rostral to 
caudal manner.  The total number of orexin neurons and the number of cFos 
expressing orexin neurons was manually counted as described in Chapter 2. 
Differences between groups were evaluated with a 2-way ANOVA and posthoc-test.  
4.2.5 Microdissection and qPCR.  Microdissection procedures have been 
described in Chapter 3. For Gal-LepRbKO and WT mice, the mt and fornix were 
used for visual landmarks to strategically dissect the LHA (Figure 3.1, B-C).  LHA 
tissue pieces were combined and collected in 1.5mL centrifuge tubes, flash frozen 
in dry ice, and stored in -80°C until further processed.  
RNA extraction, RT-PCR and qPCR procedures are detailed in Chapter 2. 
cDNA (10.5ng/reaction) was analyzed in triplicate via quantitative PCR for GAPDH 
(housekeeping gene; Mm99999915_g1), orexin (Mm04210469_m1), 
OX1(Mm01185776_m1), OX2 (Mm01179312_m1); TaqMan Universal PCR Master 
Mix; Applied Biosystems-4304437, Carlsbad, CA) using an Applied Biosystems 
7500 Real-Time PCR System. Fold induction of gene expression was calculated 
using the ΔΔCT method as described in Chapter 2. 
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4.3 RESULTS 
4.3.1 Gal-LepRb neurons innervate orexin neurons and the LC. To 
understand how Gal-LepRb neurons may regulate the observed effects on natural 
reward behavior, we aimed to identify the anatomical sites and neurons that were 
innervated by both galanin and LepRb neurons from the LHA.  
We first injected the adenoviral construct Ad-iZ/EGFPf into the LHA of 
LepRbCre or GalCre mice, which resulted in a cre-specific expression of a 
farnesylated enhanced green fluorescent protein (EGFPf) and a non-cre dependent 
β-galactosidase expression from all adenovirus infected cells (Figure 4.1, A-G). The 
farnesylation anchors EGFPf to the cell membrane, which enhances the 
visualization of thin axonal processes, the β-galactosidase expression, is used to 
track the spread of overall virally infected cells. In a second step, we injected 
another adenoviral construct, Ad-iN/WED, that resulted in the cre-dependent 
expression of wheat germ agglutinin (WGA) and the fluorescent protein DsRed. 
WGA can be transported anterogradely and transsynaptically into 2nd order 
neurons, while DsRed is restricted to 1st order neurons (here LepRb or galanin 
neurons; Figure 4.1, G-L). 
Correctly targeted Ad-iZ/EGFPf injection into the LHA of LepRbCre (Figure 
4.1, A) or GalCre (Figure 4.1, D) mice was immunohistochemically visualized by 
staining for EGFPf (green) and β-galactosidase (red). EGFPf positive cell bodies 
represent LepRb or galanin neurons and many fibers are seen from LepRb and 
galanin neurons projecting locally within the LHA (Figure 4.1, A and D, 
respectively). Similarly, Ad-iN/WED injection into the LHA of LepRbCre or GalCre 
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mice, respectively, results in WGA labeling within the LHA, where 1st order neurons 
are identified by WGA and DsRed expression (= yellow neurons) and many 2nd 
order neurons that are only positive for WGA (= green neurons) (Figure 4.1, G and 
J). Thus, Gal-LepRb neurons intensely innervate local LHA neurons. 
We further confirmed that LHA LepRb neurons strongly innervate the VTA 
(Figure 4.1, B and H) as had been reported earlier (Leinninger et al. 2011, Louis et 
al. 2010). In contrast, we rarely found projections or second order labeled neurons 
to the VTA from LHA galanin neurons (Figure 4.1, E and K), suggesting that Gal-
LepRb neurons are unlikely to substantially innervate the VTA.  
Instead we found that both – LHA LepRb and galanin neurons - strongly 
innervated the LC (Figure 4.1, C and F), a site that had not yet been associated 
with leptin function. With Ad-iN/WED we found many 2nd order neurons labeled 
from LHA galanin neurons (Figure 4.1, L), and we also found an occasional 2nd 
order labeling from LHA LepRb neurons (Figure 4.1, I), however, 2nd order 
tracing from LHA LepRb neurons was not observed in all cases of injected 
animals. Thus, we further injected the retrograde tracer fluorogold (FG) into the 
LC of GalYFP mice, and analyzed the brains for the existence of leptin-induced 
pSTAT3 neurons co-localized with GalGFP and retrogradely labeled with FG from 
the LC (=FG/pSTAT3/GalGFP positive; Figure 4.2). Galanin is well known to be 
co-expressed in the majority of LC neurons (Moore and Gustafson 1989) so that 
the GalGFP signal served as a great visual outline for the LC and to verify the 
accuracy of FG injections (Figure 4.2, A).  
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Figure 4.1	  Gal-LepRb neurons project to the LC, but not the VTA. A. Injection of Ad-
iZ/EGFPf into the LHA of LepRbCre mice shows the spread of infected neurons in 
red (β-galactosidase expression). Cre-recombination removes β-galactosidase 
expression and induces EGFPf expression (green, representing LepRb neurons). 
LHA LepRb neurons project into the VTA (B.) and LC (C.). D. Injection of Ad-
iZ/EGFPf into the LHA of GalCre mice, again with spread of infected neurons in red 
(β-galactosidase expression) and neurons with cre-expression in green (EGFPf). 
LHA Gal neurons do not project into the VTA (E.), but strongly innervate the LC 
(F.). G. Injection of Ad-iN/WED into the LHA of LepRbCre mice (n=7) shows infected 
first order neurons by co-expression of cre-inducible DsRed (red) and wheat germ 
agglutinin (WGA, green)(yellow labeling). The anterograde and transsynpatic tracer 
WGA is further transported into second order neurons indicated by single WGA 
labeling (green) within the LHA (G.), VTA (H.) and LC (I., only observed in one 
animal). J. Injection of Ad-iN/WED into the LHA of GalCre mice (n=6) shows local 
first order neurons (yellow) and second order neurons (green) are found in the LHA 
(J.) and LC (L.), but not the VTA (K.).  
 
	  	   79 
 
   
 
 
 
	  	   80 
Indeed, we found many triple labeled FG/pSTAT3/GalGFP neurons surrounding the 
fornix (Figure 4.2, B) supporting the projection of Gal-LepRb neurons to the LC. 
Neurons in the LC are the major source of central norepinephrine and express 
tyrosine hydroxylase (TH). Thus, we further confirmed that galanin-derived WGA 
labeled LC neurons are indeed co-localized with TH (Figure 4.3, C).  
LepRb neurons in the LHA innervate local orexin neurons (Louis et al. 2010), 
thus, we further tested if the WGA labeled 2nd order neurons from LHA LepRb or 
galanin neurons might in fact be orexin neurons. Indeed, we found that many WGA 
labeled from LHA LepRb and galanin neurons were co-stained with orexin (Figure 
4.3, A and B, respectively). Importantly, we showed earlier that neither LepRb nor 
galanin neurons are co-localized with orexin (data shown in Chapter 2) 
demonstrating that Gal-LepRb neurons innervate orexin neurons.  
 
 
Figure 4.2 Gal-LepRb neurons innervate the LC. GalYFP mice were injected the 
retrograde tracer fluorogold (FG, red) into the LC (A), and within the LHA brains 
were analyzed for the existence of leptin-induced pSTAT3 (red) neurons co-
localized with GalGFP (blue) and retrogradely labeled with FG (green) from the 
LC (B).  
 
A. B. 
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4.3.2 Galanin mediated inhibition of orexin neurons. LHA galanin and 
GaR1 expression was decreased in Gal-LepRbKO mice (Chapter 3) and galanin is 
known for its potent inhibitory action in many neuronal systems, including the 
hypothalamus (Dong, Tyszkiewicz, and Fong 2006). Thus, if galanin would be 
significantly involved to mediate inhibitory leptin action onto orexin neurons, we 
predicted that Gal-LepRbKO mice would show increased activation of orexin 
neurons. To test this we analyzed the brains of Gal-LepRbKO mice and WT 
littermates for their basal level of cFos (as a surrogate for neuronal activation) in 
orexin neurons.  
 
Figure 4.3 Gal-LepRb neurons innervate local orexin neurons and noradrenergic LC 
neurons. A. In LepRbCre mice injected with Ad-iN/WED into the LHA many WGA 
neurons are co-expressed locally with orexin.  B. In GalCre mice injected with Ad-
iN/WED into the LHA many WGA neurons are co-expressed locally with orexin and 
within the LC WGA neurons co-expressed TH, depicting noradrenergic neurons (C.). 
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Indeed, we found that specifically the rostral portion of orexin neurons from 
Gal-LepRbKO mice had a higher percentage of cFos positive orexin neurons 
compared to WT littermates (Figure 4.4, A-E; n=5, pANOVA<0.003, * pHolm-Sidak<0.05). 
This was due to an increased number of cFos/orexin neurons (Figure 4.4, D), while 
the total number of orexin neurons was unchanged or decreased (Figure 4.4, E). 
This was further confirmed with qPCR, where LHA orexin gene expression 
remained unchanged between WT and Gal-LepRbKO mice (Figure 4.4, G). 
Interestingly, within the LHA the gene expression of orexin receptor 2 (OX2), but 
not orexin receptor 1 (OX1), was significantly decreased (Figure 4.4, G; *pt-
test<0.02), suggesting that increased activation of orexin neurons may preferentially 
act via OX1 in the LHA.  Furthermore, we establish that orexin neurons are co-
labeled with GalR1 (Figure 4.4, F), further supporting that circulating (baseline) 
leptin levels provide an inhibitory tone onto orexin neurons that is mediated by 
galaninàGalR1 signaling (Figure 4.4, H). 
 
4.4 DISCUSSION 
Our data outline a novel neuronal circuit where Gal-LepRb neurons 
directly innervate orexin neurons as well as noradrenergic neurons in the LC, 
but were not found to substantially innervate the VTA directly. While leptin 
stimulates inhibitory acting galanin expression in the LHA the lack of leptin 
action in galanin neurons robustly decreased galanin expression, and resulted in 
enhanced activation of orexin neurons.  
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Figure 4.4 Enhanced orexin activation in Gal-LepRbKO mice. IHC stain of nuclear 
cFos (red nuclear stain, as a surrogate for neuronal stimulation) and orexin-A 
(green stain) in WT (A) and Gal-LepRbKO mice (B). C. Percentage of total orexin 
neurons co-labeled for orexin and cFos in WT and Gal-LepRbKO mice; extending 
from the most rostral portion of the orexin population (Section 1) to the most caudal 
portion (Section 4). pANOVA<0.05; *pt-test<0.05, n=5.  Total number of cFos/orexin 
positive neurons (D) and total orexin cells (E) were not significantly different 
between Gal-LepRbKO and WT mice. F. IHC stain of orexin-A (red) and GalR1 
(green) showed orexin neurons expressed the GalR1.  G. Gene expression 
analysis of microdissected LHA tissue showed no difference in orexin or orexin 
receptor 1 (OX1) mRNA, however orexin receptor 2 (OX2) was significantly 
decreased (pttest <0.05, n=10-13).  H. Hypothesized circuit establishing leptin-
mediated inhibition of orexin neurons via galaninàGalR1 signaling. 
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In line with this observation, orexin is known to stimulate sucrose intake (Baird et al. 
2009), while orexin receptor deficient mice have reduced sucrose intake (Matsuo et 
al. 2011).  Pharmacological blockade of orexin receptors partially prevents fasting-
induced increases of palatable food intake (Rodgers et al. 2001). Thus, the 
observed increase in sucrose consumption in Gal-LepRbKO mice (Chapter 3) and 
increased activation of orexin neurons suggests that leptin action on LHA galanin 
neurons mediates fasting induced sucrose consumption.  
Importantly, Gal-LepRb neurons strongly innervate noradrenergic neurons in 
the LC.  Similarly, the LC is the major projection sites of orexin neurons (Peyron et 
al. 1998) and control both arousal and reward (Sakurai and Mieda 2011). The LC is 
the sole NE source for many central sites (e.g. prefrontal cortex, PFC), while other 
sites (e.g. hypothalamus) receive additional NE input from the brainstem (NTS). 
Leptin treatment decreases and leptin deficiency increases hypothalamic NE levels, 
while activation of the α-2-adrenoceptor substantially increases hyperphagia in 
leptin deficient obese mice (Kutlu et al. 2010, Currie and Wilson 1991, 1992, 1993). 
Altogether, innervation of such prominent nuclei that regulate reward-driven 
behaviors provides an intriguing circuit for future investigation of LHA-leptin action. 
Importantly, our data shows that Gal-LepRb neurons utilize a novel LHA LepRb 
circuit where leptin acts to inhibit orexin neurons via leptin-evoked galaninàGalR1 
signaling in orexin neurons. 
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CHAPTER 5. CONCLUSION 
 
5.1 GAL-LEPRB NEURONS ARE A NOVEL LEPRB POPULATION 
 
Through the investigation of the LHA-LepRb subpopulation, as characterized 
by LepRb neurons co-expressing the inhibitory neuropeptide galanin (Gal-LepRb 
neurons), our data establishes that Gal-LepRb neurons mediate anorexigenic leptin 
action via modulation of reward circuits that govern nutrient intake. Gal-LepRb 
neurons are stimulated by leptin and leptin-induced stimulation of galanin neurons 
elicits inhibitory effects onto synapsing neurons either via the inhibitory 
neurotransmitter GABA or galaninàGalR1 mediated signaling.  We found that Gal-
LepRb neurons are a distinct population from two well-established orexigenic-
influencing LHA populations: the melanin concentrating hormone (MCH) and orexin 
neuronal populations.  However, we did identify additional subpopulations within the 
Gal-LepRb population. We show that 30% of Gal-LepRb neurons were found to 
additionally express the anorexigenic peptide cocaine-amphetamine regulated 
transcript (CART), as well as, a considerable portion of galanin neurons that co-
expressed neurotensin (Nts).  
 Recently, Leinninger et al., reported on findings that characterized a LHA 
LepRb subpopulation co-expressing Nts (Nts-LepRb neurons). Like Gal-LepRb 
neurons, Nts-LepRb neurons innervate local orexin neurons, however, Nts-LepRb 
neurons were shown to directly project to the VTA (Leinninger et al. 2011).  
Importantly, Gal-LepRb neurons are distinguished from Nts-LepRb neurons, as Gal-
LepRb neurons were not observed to project to the VTA.  Furthermore, we show 
that Gal-LepRb neurons innervate the noradrenergic neurons of the LC, a finding 
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that was also not reported for Nts-LepRb neurons. The LC also receives dense 
projections from orexin neurons (Peyron et al. 1998) and is largely recognized for 
influencing arousal, addiction and withdrawal pathways (Rasmussen et al. 1990, 
Nestler 1992, Kutlu et al. 2010).  
  Importantly, the LC was a nucleus that had yet to be identified as a potential 
target of leptin action, and provides an intriguing circuit for investigating the role of 
Gal-LepRb neurons in aspects of arousal, addiction and nutrient selection. For 
example, we know that the LC is the sole norepinephrine (NE) source for many 
central sites. Leptin deficient ob/ob mice exhibit increased hypothalamic NE levels 
while leptin treatment decreases hypothalamic NE levels. Moreover, ob/ob mice 
given a low dose of the α-2-adrenoceptor agonist clonidine were observed to 
selectively increase carbohydrate intake {while protein and fat intake remained 
unaltered (Currie and Wilson 1991)}. This would implicate a potential role for leptin 
in regulating NE-mediated nutrient selection, possibly via leptinàGal-LepRb-
mediated inhibition of the LC. Our data indicates that Gal-LepRb neurons represent 
a novel LHA LepRb population capable of mediating homeostatic mechanisms of 
energy balance and reward function as proposed in the illustrated Gal-LepRb circuit 
schematic shown in Figure 5.1. 
 
5.2 GAL-LEPRB NEURONS MEDIATE APPETITIVE BEHAVIORS VIA REWARD 
CIRCUITS 
 
  To establish the physiological importance of Gal-LepRb neurons we 
developed a mouse model with a targeted deletion of LepRb specific to galanin 
neurons; termed Gal-LepRbKO mice. We show that Gal-LepRbKO mice exhibit 
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reward system as largely observed by their differential preferences for palatable 
sucrose and lipid solutions and their enhanced food-motivated behaviors on the 
incentive runway. There are two predominant systems governing behaviors 
associated with food rewards: the mesolimbic dopamine system and the opioid 
system. To gain further insight as to how these reward pathways were altered, we 
compared expression profiles of markers specific to each system in Gal-LepRbKO 
and WT mice. Indeed, we found that Gal-LepRbKO mice have reduced DA content 
within the NAc (Figure 5.2) as well as decreased µ-opioid receptor gene expression 
within the NAc and LHA (Figure 5.3).  
 
 
Figure 5.1 Schematic of proposed Gal-LepRb circuit. 
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Figure 5.2 Gal-LepRbKO mice have decreased dopamine content in the NAc. HPLC 
detection of total dopamine content from microdissected NAc tissue (methods 
described in Chapter 3) in Gal-LepRbKO and WT mice (n=7-8; pt-test <0.05). 
 
 
Figure 5.3 µ-opioid receptor gene expression is decreased in the LH and NAc of 
Gal-LepRbKO mice. µ-opioid receptor mRNA fold change from microdissected tissue 
from the LH and NAc (n=10-13; pt-test <0.05) in Gal-LepRbKO and WT mice. 
(TaqMan probes: GAPDH, housekeeping gene= Mm99999915_g1; µ-opioid 
receptor Mm01188089_m1). Fold induction of gene expression was calculated 
using the ΔΔCT method (refer to Chapter 3 for complete microdissection techniques 
and Chapter 2 for qPCR methodology). 
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It is now widely acknowledged the properties that determine the reward 
value of nutrients are mediated by two distinguishable mechanisms: reward “liking” 
and reward “wanting” (Berridge, Robinson, and Aldridge 2009). In this theory “liking” 
refers to the pleasantness or hedonic value of food and is primarily associated with 
opioid neurotransmission.  On the other hand, “wanting” refers to the incentive 
value or motivational properties of a given stimulus, which is primarily a function of 
the mesolimbic dopaminergic system. Central pathways that regulate “liking” and 
“wanting” behaviors are highly relevant for studying the underlying mechanisms 
linked to diet-induced obesity.  For instance, in rodent models of diet-induced 
obesity higher concentrations of sucrose and lipid solutions are required to achieve 
similar “liking” responses as those observed in lean individuals (Shin et al. 2011). 
Therefore in obesity, a much higher threshold must be reached to attain the 
expected pleasure response from palatable foods. In contrast, obesity-induced 
changes in both palatable food “liking” and “wanting” responses are reversed by 
leptin (Shin et al. 2011, Davis, Choi, and Benoit 2010, Figlewicz 2003, Figlewicz et 
al. 2004, Figlewicz and Benoit 2009). 
5.2.1 Food-motivated “wanting” and the reward deficiency hypothesis. 
Activation of the mesolimbic dopaminergic system, and largely dopamine release in 
the NAc (mesoaccumbal DA pathway) plays a critical role in the reinforcing and 
motivational aspects attributed to reward “wanting” (Berridge and Robinson 1998, 
Ostlund et al. 2011, Pecina et al. 2003). Palatable foods high in sugar are potent 
stimulators of dopamine release (Hajnal, Smith, and Norgren 2004, Rada, Avena, 
and Hoebel 2005). We report that Gal-LepRbKO mice exhibit a marked increase in 
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their sucrose intake over lipids and demonstrate greater “wanting” for a sugary treat 
on the incentive runway.  However, we found that NAc DA content was significantly 
reduced in Gal-LepRbKO mice compared to WT mice. This finding seemed 
somewhat contradictory to our behavioral findings as we predicted DA content, if 
anything, would be increased in Gal-LepRbKO mice.  In light of this, we found that 
decreases in mesoaccumbal DA signaling, do not always translate into reduced 
reward-motivated behaviors. In fact, deficiencies in dopamine signaling are highly 
correlated with addictive-like behaviors and are observed by the strong “wanting” 
for a reward reinforcer (Blum et al. 2000, Comings and Blum 2000). This 
phenomenon is interpreted by the reward deficiency hypothesis, which explains that 
reward deficient individuals (a genetically or environmentally-induced down 
regulation of DA signaling) typically experience a heightened sense of 
unpleasantness even in presence of a rewarding stimulus. In order to alleviate the 
perceived negative state, they generally demonstrate greater reward-seeking and 
reward-taking behaviors as an attempt to restore mesoaccumbal DA signaling.  
Therefore, it is possible that the reduced NAc dopamine content observed in Gal-
LepRbKO mice is perceived as a reward deficit and thus translates into their 
enhanced food-motivated behaviors. As mentioned, Gal-LepRb neurons project to 
and inhibit orexin neurons. In parallel, fasting-induced decreases in circulating leptin 
would likely diminish leptin’s inhibitory influence. With the removal of this inhibitory 
block, orexin neurons increase their activity and thereby stimulate mesoaccumbal 
DA release. In the case that orexin neurons are kept in a chronic state of activation, 
as evident in Gal-LepRbKO mice, a deficient reward response is likely to manifest 
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due to an exhausted mesoaccumbal DA system. However, more precise 
methodology to quantify aspects of dopamine signaling (such as release, re-uptake, 
synthesis, etc.) in Gal-LepRbKO mice is necessary to fully support this hypothesis.   
5.2.2 Macronutrient selection and “liking”. The pleasantness or the 
hedonic value attributed to food “liking” is governed by opioid neurotransmission.  
Particularly signaling via the µ-opioid receptor within the NAc has been shown to 
increase food intake with a predominant effect on increasing fat consumption 
(Zhang, Gosnell, and Kelley 1998).  Hypothalamic galanin administration also 
preferentially increases fat intake (Tempel, Leibowitz, and Leibowitz 1988) and 
galanin is known to influence µ-opioid receptors via GalR1 signaling in reward 
pathways (Holmes et al. 2012). 
Here we report that Gal-LepRbKO mice show decreased fat consumption as 
assessed in a two-bottle choice test (when paired with sucrose or given alone).  In 
parallel with the increased fat consumption observed in animals after administration 
of either galanin or µ-opioid receptor agonists, we show that LHA galanin, GalR1 
and µ-opioid receptor gene expression is decreased in Gal-LepRbKO mice. Hence, 
the down regulation of µ-opioid receptors and galanin signaling (specifically galanin 
signaling via GalR1) likely contributes to the decreased “liking” of fats observed in 
Gal-LepRbKO mice.  In contrast, Gal-LepRbKO mice demonstrated a robust 
preference for sucrose in the two-bottle choice test.  The differential preference 
exhibited by Gal-LepRbKO mice specifies that lipids are less “liked” and highlights a 
potential mechanism by which galanin and µ-opioid receptor signaling selectively 
defines the pleasantness perceived when fats are consumed. Thereby suggesting 
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the existence of diverging circuits, which would selectively govern the hedonic 
properties of sucrose or fats, respectively. Hence WT mice, with normal galanin and 
µ-opioid receptor function, will demonstrate equal “liking” of sucrose and fats (as 
observed in two-bottle choice test) because the competition between the diverging 
circuits governing fat and sucrose intake is matched accordingly. The existence of 
dissociable pathways influencing sucrose intake has also been suggested, where 
the mesoaccumbal DA system drives sucrose “wanting,” in a manner that is 
independent from the hedonic “liking” component of sucrose (Pecina et al. 2003). 
As observed with drugs of abuse that induce abnormally high DA release, drug 
addicts report higher ratings of drug “wanting,” but no longer experience pleasure or 
“like” the drug (Evans et al. 2006). Similarly, addictive-like behaviors (comparable to 
“wanting”) have been reported in models of sugar bingeing but not observed for fat-
bingeing (Hoebel et al. 2009, Avena, Rada, and Hoebel 2009). This suggests that 
the behaviors mediating lipid consumption are dictated through a pathway 
independent from “wanting,” and potentially involve the galanin and opioid systems.  
In summary, neural circuits guiding food choice are clearly not the result of one 
prevalent pathway. Instead, mechanisms driving the intake of select macronutrients 
seems to be differentially regulated through distinct signaling pathways that function 
to encourage food selection based on the needs of the body. 
5.2.3 Implications for orexin neurons in the Gal-LepRb pathway. Orexin 
has been implicated in the activation of central hedonic hotspots that increase 
“liking,” as well as enhancing “wanting” for food rewards. Numerous reports provide 
evidence that show the activation of orexin neurons (and when orexin is centrally 
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injected) evokes reward-driven, locomotor responses (food-seeking, “wanting”) 
associated with increased mesoaccumbal DA release (Choi et al. 2010, Thorpe et 
al. 2005, Sharf et al. 2010, Harris, Wimmer, and Aston-Jones 2005).  However, 
through a distinguishable circuit, the pleasantness or “liking” of palatable foods is 
amplified via opioid signaling within distinct hedonic “hotspots”. Projections from 
orexin neurons to one such “hotspot,” the ventral pallidum, holds implications for the 
divergent actions of orexin to regulate different aspects of nutrient reward. A recent 
study showed that injections of the orexin peptide into the ventral pallidum induced 
a marked increase of positive “liking” reactions to sucrose solutions, but had no 
effect sucrose “wanting” (Ho and Berridge 2013). Thus, orexin signaling within this 
distinct hedonic nucleus influences opioid-mediated “liking” responses. Moreover, 
µ-opioid receptors are expressed on orexin neurons (Georgescu et al. 2003), and 
endogenous opioids are required for orexin-mediated feeding (Clegg et al. 2002). 
Indeed, the activation of NAc µ-opioid receptors amplifies “liking” reactions and 
increases food intake. µ-opioid receptor activation in the NAc also increases the 
activity of orexin neurons. However, when orexin receptors in the VTA are blocked, 
food intake is no longer increased by NAc µ-opioid receptor activation (Zheng, 
Patterson, and Berthoud 2007). Taken together, orexin neurons appear to serve as 
a hub for the integration of signals relaying nutritional status (i.e. fasting/ or low 
leptin) and information regarding the value of a food reward. This signal 
convergence is then translated into specific appetitive behaviors based orexin’s 
distinct anatomical projection targets to effect both reward “liking” (via µ-opioid 
receptors in hedonic nuclei) and reward “wanting” (via mesoaccumbal DA pathway).  
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In light of this, we know that leptin reduces palatable food “liking” and 
“wanting” behaviors, and these effects are most likely the outcome of leptin-
mediated inhibition of orexin neurons. Consistent with previous findings (Leinninger 
et al. 2009, Louis et al. 2010), we confirmed that LepRbs are not expressed on 
orexin neurons, demonstrating that leptin inhibits orexin neurons indirectly.	  But the 
LepRb population that mediates this inhibitory leptin effect onto orexin neurons is 
unknown.  
The here presented work shows convincing evidence that Gal-LepRb 
neurons in the LHA mediate an inhibitory effect onto orexin neurons.  As we found 
that abolishing leptin signaling exclusively in galanin neurons increases the 
activation level of orexin neurons. Consistent with this, Gal-LepRbKO mice show 
enhanced motivation to obtain a sugary food reward on the incentive runway. Our 
data further establishes a functional circuit responsible for mediating these effects. 
We show that leptin stimulates GABAergic Gal-LepRb neurons, promoting synaptic 
release of the inhibitory neuropeptide galanin (and/or the inhibitory 
neurotransmitter, GABA). Gal-LepRb neurons innervate local orexin neurons. 
Additionally, we determined that orexin neurons express the Gi-coupled GPCR 
galanin 1-receptor (GalR1), validating the cellular ability of orexin neurons to 
respond to inhibitory galanin action. Altogether, these data demonstrate that leptin-
mediated galanin release from LHA Gal-LepRb neurons mediates the inhibitory 
tone onto orexin neurons. Our findings reveal that Gal-LepRb neurons are a novel 
LHA LepRb population that regulates the rewarding value of nutrients via control of 
orexin neurons. 
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